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1. Introduction
Melanoma  genetics  has  been  for  a  long  time  a  great  challenge  to  cancer  biologists,  in
part due to a complete lack of a single candidate gene to melanoma development. Differ‐
ent from breast and colorectal cancers, where BRCA-1/2 and APC/mismatch repair genes,
respectively,  characterize  familial  clusters  of  cancer  susceptibility  (reaching  penetrance
rates as high as 90% in some cases),  in melanomas,  the mutation rate of the most com‐
monly altered genes associated with disease progression do not exceed 60% of the cases
in  familial  clusters.  Among  the  “classical  melanoma  genes”  are  those  coded  at  the
CDKN2A locus (coding for p14 and p16, both related to cell cycle arrest), BRAF (specially
the V600E mutation),  a downstream transducer of the RAS signaling pathway and criti‐
cal for the cellular response to growth signals, and mutations in NRAS, somewhat relat‐
ed to initiation and progression of melanoma.
However,  alterations in those genes,  either by mutations or by epigenetic  alterations do
not account for all melanoma cases. Moreover, the mutations found in the classical mela‐
noma genes are not typical UV signature mutations (such as C to T transitions). This ob‐
servation poses  an  interesting  problem in  melanoma biology.  Extensive  epidemiological
data indicates that intermittent exposure to UV radiation, mainly UVB is a major etiolog‐
ic  factor  for  melanoma  development.  On  the  other  hand,  genes  commonly  mutated  in
melanomas lack UV signature mutations. Thus, evidence so far for the presence of UVB-
generated  signature  mutations  in  melanoma  that  could  be  defined  as  driver  mutations
has been less than compelling. Two critical questions need therefore to be answered; (1)
If  the  classical  melanoma  genes  do  not  account  for  the  majority  of  cases,  what  other
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genes are involved in melanomagenesis?  And,  (2)  what  is  the real  relationship between
the mutagenic potential of UV radiation and melanoma genetics?
In the following pages, we will discuss the new findings about the biology of this neoplasia,
besides discussing the known genes involved in melanomagenesis. A systematic review of to
date GWAS data, deep-sequencing data and functional genomics will serve as the background
for this discussion. As examples, GWAS studies have identified genetic variations in genes
related to pigmentation that confer susceptibility to melanomas. The importance of these
studies resides in the identification of new variants that can represent low penetrance sus‐
ceptibility genes. Other classes of genes that have emerged as critical genes to melanoma are
DNA repair genes, especially NER genes (Nucleotide Excision Repair – a pathway that repair
typical UV DNA damages). New studies have identified polymorphisms in those genes that
confer higher risk to melanoma development. This susceptibility, in an interesting manner,
seems to be influenced by the UV index of a certain region. On the other hand, microarray
studies have suggested that DNA repair genes may be critical to metastasis sucess of melano‐
mas, through stabilization of a “metastatic genome”. Deep-sequencing studies of melanoma
cells have also identified genes and patterns of mutational status that correlate with UV
signatures, bringing new clues to melanoma genetics. Are these driver or passenger mutations?
The importance of other genes and pathways is also highlighted. One good example of a gene
involved with melanoma progression is the Microphthalmia-associated transcription factor
(MITF). MITF has been found to be expressed in several melanomas and its function is related
to a diversity of cell processes, contributing to melanoma progression. The importance of TP53
gene and its pathways in melanocyte/melanoma biology is also discussed. The TP53 gene has
intrigued biologists for a long time, since its mutational frequency is very low in melanomas,
differently from other skin cancers, which harbor a high frequency of p53 mutations, which in
turn are UV-type mutations. Functional data indicate however that the p53 pathway is
dysfunctional in melanomas. What are the bases for this malfunction in this critical pathway
for genome stability?
Thus, in this chapter we discuss both the “old” and the “new” genetics of melanoma suscept‐
ibility and progression. A discussion that will allow for the readers a systematic overview of
what is known about the classical melanoma genetics, at the same time that may provide the
basis to explore the new concepts that are emerging in this field.
2. UV exposure, deep-sequencing and melanomas – Understanding the
melanoma development in depth
Skin constitutes the first defense barrier in protection of internal environment and it is therefore
subjected to several aggressions by pathogenic microorganisms or by chemical or physical
damaging agents. Among these several agents, sunlight ultraviolet radiation (UV) is consid‐
ered the most potent carcinogenic factor for skin cancers, although the precise relationship
between dose, time and nature of sunlight exposure to skin cancer development remains
controversial [1]. Ultraviolet radiation can be classified according to its wavelength in UVA
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(320-400 nm), UVB (280-320 nm) and UVC (200-280 nm). Despite the fact that UVA is more
abundant in sunlight (90 %), UVB is about 1000-fold more efficient to cause sunburns and DNA
damage than UVA [2]. Skin exposure to UV light affects epidermal and dermal cell survival
and proliferation, besides other cutaneous functions [3]. Acute effects of UV exposure are
usually the most harmful, including DNA damage, apoptosis, erythema, immunosuppression,
all factors contributing to aging and skin cancer [4].
One  of  the  main  effects  of  UV  exposure  on  cancer  development  is  direct  damages  to
DNA. Photoreactions due to absorption of UV (mainly UVB) by DNA lead to the estab‐
lishment  of  covalent  linkages  of  adjacent  pyrimidine  bases  (cytosine  or  thymine)  thus
forming cyclobutane pyrimidine dimers (CPD) and 6-4 photoproducts.  CPDs are consti‐
tuted  by  the  ligation  of  C-4  and  C-5  carbons  in  both  pyrimidines,  whereas  6-4  photo‐
products are produced between C-6 and C-4 carbons of two adjacent pyrimidines, more
frequently  between  TC  and  CC  residues.  CPDs  are  also  considered  more  carcinogenic
than 6-4  photoproducts,  the  frequency  of  CPD formation  is  three  times  higher  and are
less efficiently repaired [5]. If not repaired, both photoproducts lead to genetic mutations
such as C→T and CC→TT transitions, besides single and double strand breaks on DNA
[6]. Other genotoxic agents associated with excessive exposure to UV are reactive oxygen
species (ROS),  characterizing an indirect  effect  of  radiation [7].  ROS can promote deani‐
mation and adduct formation, leading to errors in base pairing and, thus, mutations and
chromosomal reorganization, contributing to carcinogenic process.
Epidemiologic  studies  have  indicated  that  a  pattern  of  intense  and  intermittent  expo‐
sure  to  sunlight  is  a  major  risk  factor  for  developing  melanoma  [8].  History  of  skin
sunburns  have  been frequently  used as  measure  to  intermittent  exposure  and can be  a
marker  for  high  risk  of  melanoma  development.  One  or  more  severe  sunburns  on
younger  ages  increase  the  risk  of  melanoma  [9-11].  Besides  the  clear  risk  attributed  to
sunlight  and  thus  UV  exposure  in  melanomagenesis,  the  lack  of  a  typical  signature  of
UV  mutation  in  genes  classically  related  to  melanoma  development  and  progression
had  intrigued  researchers  for  years.  First,  CDKN2A  and  CDK4  genes  had  inheritable
mutations  and  thus  not  showed  typical  UV  mutations.  Even  somatic  alterations  in
CDKN2A  show  very  low  levels  of  UV  mutations  and  the  majority  of  CDKN2A  altera‐
tions  in  melanomas  are  epigenetic  silencing  and  homozygous  deletions  [12].  Regarding
NRAS,  another  “old  gene”  involved  with  melanoma  progression,  the  most  commonly
described  mutation  lies  in  codon 61  and does  not  correspond to  typical  UV mutations
(CAA(Gln)  to  AAA(Lys)  or  CAA(Gln)  to  CGA(Arg))  and  can  be  found  in  about  10%
of  somatic  melanomas  [13].  Regarding  BRAF  mutation,  the  most  prevalent  V600E
(found in  about  40% of  melanomas  –  [14]),  shows  a  transversion  of  thymine  substitut‐
ed by adenine.  Finally,  regarding the  PTEN  gene,  increased allelic  loss  can be  detected
ranging  to  40  to  60%  of  melanoma  cases;  less  than  10%  of  melanoma  samples  show
mutations  in  PTEN,  the  extensive  majority  consisting  of  frameshift  mutations  [15].  All
those  cited  reports  are  the  opposite  to  the  high  frequency  of  typical  UV  mutations  in
critical  genes  related  to  the  other  two  skin  cancers,  namely  basal  cell  carcinomas  and
squamous cell  carcinomas,  such as  TP53  [16].
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In a seminal study, a comparison of four distinct sets of melanomas at the genomic level
gave  important  clues  about  the  role  of  UV in  melanomagenesis  [17].  The  authors  com‐
pared the  number  of  copies  of  DNA and the  mutational  status  of  two critical  genes  to
melanoma development,  BRAF  and NRAS  in a panel consisting of 126 melanomas from
four groups differing among them according the degree of exposure to ultraviolet  light:
30  melanomas  from  skin  with  chronic  sun-induced  damage;  40  melanomas  from  skin
without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and
20 mucosal  melanomas.  The results  indicated that  melanomas from sun-protected areas
(acral and mucosal) had more frequent chromosomal aberrations including amplifications
and  losses  compared  to  sun-exposed  melanomas.  Frequent  amplification  was  identified
in  CCND1  gene  (cyclin  D1 gene)  and CDK4  gene  (more  frequent  in  acral  and mucosal
melanomas).  Moreover,  deletions  of  the  CDKN2A  locus  in  were  found in  50  percent  of
all  melanomas, making it  the most commonly lost  genomic region, being also more fre‐
quent  in  acral  and  mucosal  melanomas).  Mutations  in  BRAF  gene  were  significantly
more  common  in  the  group  of  melanomas  that  were  on  skin  without  chronic  sun-in‐
duced  damage  than  in  the  other  three  groups.  Therefore,  there  are  distinct  patterns  of
genetic  alterations  in  the  four  groups  of  primary  melanomas.  The  differences  in  both
chromosomal  aberrations  and the  frequency of  mutations  of  specific  genes  suggest  that
these tumors develop through different mechanistic routes,  and likely respond to differ‐
ent selective influences.
The unanswered question about the real impact of UV light on melanoma genetics began
to  be  solved  with  the  development  of  new  technologies  in  DNA  sequencing,  the  so
called  “deep-sequencing  method”.  With  this  technology,  the  researchers  could  perform
large-scale  sequencing,  covering  the  whole  genome.  In  one  of  the  first  studies  using
deep-sequencing methods, the authors reported more than 1000 mutations using 210 di‐
verse human cancers, including melanomas [18]. This study covered 274 megabases (Mb)
and was restricted to  518 protein kinase genes.  The results  showed that  melanomas (in
that  case,  melanoma  cell  lines),  had  a  high  prevalence  of  mutations  showing  a  mean
number  of  18.54  mutations  per  Mb of  DNA. The main result  from this  first  study was
that  of  144 mutations in  melanomas,  more than 90% was C to  T mutations,  the typical
transition  of  UV-related  mutations.  Most  somatic  mutations  found  were  classified  as
“passengers”  mutations,  i.e.  those  which  do  not  contribute  directly  to  carcinogenesis.
“Driver” mutations, those mutations that contribute to carcinogenesis, were found in ap‐
proximately 120 genes.
A second study, in this time a comprehensive catalogue of the whole genome of a melanoma
cell line and a lymphoblastoid cell line from the same person, provided the first catalogue of
somatic mutations from an individual cancer [19]. The numbers generated by the deep-
sequencing are impressive. The study identified 33345 somatic mutations, where 32325 were
single base mutations and 510 were double-base mutations. A total of 292 somatic base
substitutions were in protein-coding sequences and of these, 187 were non-synonymous
mutations leading to amino acid changes, including 172 missense mutations and 15 nonsense.
Several individual substitutions highlighted novel candidate cancer genes such as mutations
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in SPDEF gene, which codes to an ETS transcription factor family, described as associated with
some cancers types [20]. Moreover, mutations in MMP28 gene (a member of matrix metallo‐
proteinases) and in UVRAG (a putative tumor suppressor gene – [21]) were found. In addition,
a 12-kilobase internal homozygous deletion was found in PTEN gene.
Of the total number of mutations found (33345), almost 25000 were C to T mutations, and of
the 510 dinucleotide substitutions, 360 were CC to TT changes [19]. The mutational spectrum
observed is consistent with UV-associated mutations, fact that denotes the influence of UV on
melanoma development. C to T and CC to TT changes were significantly more frequent in
CpG dinucleotides than the expected by chance. The mutational pattern also indicated a strong
relation of UV mutations with the nucleotide excision DNA repair pathway (NER) due to the
high frequency of mutations in non-transcribed strands when compared to mutational
frequency in transcribed strands. The transcription-coupled repair (a sub-pathway of NER
system), which operates in transcribed strands, is credited to be more efficiently in repair UV
lesions when compared to NER system that operates in non-transcribed strands. Finally,
besides the majority of C to T mutations, the second commonest mutation frequency was
substitution of G to T. High production of ROS can lead to oxidized guanines and in turn causes
G to T changes. As UV exposure can also lead to ROS production, is tempting to suggest that
besides the direct DNA damage caused by UV, contributing to C to T changes, indirect effects
such as ROS production also may contribute to melanoma carcinogenesis. Thus, this first entire
catalogue of mutations in melanoma by whole genome sequencing supports the notion that
UV exposure plays a critical role in melanoma development.
A third whole genome sequencing study also confirmed the elevated mutational rate in
melanomas, that in mean was about 30 mutations per Mb, and the C to T mutations were the
most frequent, once again reinforcing the role of UV irradiation in melanomas [22]. However,
the great advantage of the study was using metastatic melanoma samples and also including
melanomas from different body areas. Thus, the authors could present an interesting panel of
mutational rate across the different melanoma subtypes. As example, acral melanomas showed
mutational rates comparable to other solid tumor types (3 mutations per Mb), whereas
melanomas from the trunk showed higher mutational rates. The sequencing of a melanoma
from an individual with history of chronic sun exposure exhibited the higher mutational rate
across the samples analyzed (111 somatic mutations per Mb). Moreover, that melanoma with
the higher mutational rate showed 93% of C to T substitutions, while acral melanomas showed
only 36% of such mutations. These data strongly support the contribution of sun exposure in
melanoma etiology. From the most significantly genes, the authors identified frequent
mutations in PREX2 gene, mutated in 11 of the 25 melanomas samples. PREX2 is involved
with PTEN pathway modulating its function [23]. Functional analysis by expressing the
mutant forms of PREX2 in melanocytes injected in immunodeficient significantly accelerated
in vivo tumorigenesis, suggesting that PREX2 mutations contribute to melanoma progression.
Whole genome sequence of acral melanomas also identified low frequency of mutations (2.16
per Mb in the primary tumor and 1.95 per Mb in metastasis sample) [24].
Additional studies from exome sequencing have identified new genes related to melanoma
development and also chemoresistance. From exome sequencing study performed in seven
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melanomas the authors found a total of 4933 somatic mutations, 3611 of which were located
in protein-coding regions in 2586 genes [25]. Confirming previous results, C to T transitions
were the most representative mutations (ranging from 73 to 87% of all mutations). In order to
get a more comprehensive view of melanoma genome, the authors looked to genes involved
with MAPK pathway, which includes NRAS and BRAF. Two of seven melanomas analyzed
showed a somatic G to A transition at homologous site in the MAP2K1 and MAP2K2 genes,
kinases that are downstream targets of BRAF. In an independent set of 127 melanomas, 8%
confirmed the existence of damaging mutations in either gene. Following functional studies
with either gene demonstrated a constitutive activation and resulted in ERK1/2 phosphoryla‐
tion and the oncogenic activity of such mutations was also evaluated in transformation assays.
Moreover, in four of the seven melanomas, mutations were found in FAT4, DSC1 and LRP1B
genes, which might be candidate genes, as suggested by the authors [25].
In an independent study [26], other melanoma exome sequencing also identified mutations in
genes participating of MAPK pathway, more precisely MAP3K5 and MAP3K9. Validation of
such data indicated mutations in MAP3K5 in 8 of 85 melanoma cell lines and mutation in 13
of 85 cell lines to MAP3K9. Functional analysis of such mutations indicated a significantly
reduction in kinase activity of both proteins. Moreover, such mutations in both genes resulted
in decreased levels of phosphorylated MEK-ERK and JNK, pathways involved with apoptosis,
differentiation, survival and senescence. Interestingly, decreased expression of MAP3K5 and
MAP3K9 by siRNA method led to chemoresistance to temozolomide [26]. A third exome
sequencing study, using a large sample size (147 melanomas from sun-exposed areas),
identified a recurrent UV-signature in RAC1 gene in 9.2% of cases. Biochemical and functional
analysis of mutated RAC1 showed that such alteration promotes melanocyte proliferation and
migration [27].
All of these genome sequence studies identified a great number of mutations, however most
mutations are passenger mutations. In order to differentiate passenger from driver mutations,
Linda Chin coordinated an effort to sequence exons and introns of melanoma samples,
comparing their frequency in order to identify positively selected genes, based on enrichment
of mutations in exons [28]. The authors identified positive selection in melanoma genes
including well-know genes such as BRAF, NRAS, PTEN, TP53, p16 and also indentify new
candidate genes, such as PPP6C, RAC1 (previously described in [26]), SNX31, TACC1 and
STK19. Noteworthy, to PPP6C (a subunit of PP6C protein phosphatase), a candidate to tumor
suppressor gene, showed 60% of mutations clustered within a 12 amino acid region flanking
an arginine at codon 264. Regarding RAC1, the mutant forms also indicated gain-of-function.
The study also indicated the role of UV in the advent of melanoma driver mutations. Of 262
driver mutations found in 21 genes identified by the study, 46% were caused by C to T
mutations (37%) or G to T (9%), alterations characteristics of UVB/UVA-induced mutations.
These numbers increased to 67% by excluding mutations in BRAF or NRAS genes.
Innovative strategies exploiting deep sequencing will contribute to the understanding of the
diversity of pathways involved with melanoma. We anticipate that studies of melanomas
arising in different ethnic groups, and mainly from individuals who migrated from low-UV
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index regions to high-UV index regions in the globe will help us understanding more about
the genes involved in melanomagenesis.
3. Melanoma genetics: Susceptibility genes
When we talk about susceptibility genes to diseases, especially to cancer, we are talking about
inheritable genetic alterations. Such alterations in critical genes related to tumor suppression
contribute to modulate the susceptibility to certain tumors. Inheritable alterations can be
classified as mutations or polymorphisms (also known as single nucleotide polymorphism –
SNP). Both genetic alterations have different features such as: (i) related to population allelic
frequency (mutations < 1% and polymorphisms > 1%); (ii) related to its impact to gene
functionality, where mutations cause deleterious alterations to the function while polymor‐
phisms may modify the function, however not in a deleterious manner; (iii) related to pene‐
trance, where mutations exerts its deleterious function in a high penetrance to development
of the disease. Conversely, polymorphisms exert its function in a low penetrance to disease
and may be more susceptible to environmental influence; (iv) age of tumor onset, where high
penetrance mutated genes contribute to disease development in younger ages while poly‐
morphisms are related to older ages to cancer development. Temporally, high susceptibility
genes to melanoma were well established through the years, however low susceptibility genes
have been identified recently. Appreciation of high penetrance genes came from multiple
studies of melanoma-predisposed families studies; in which linkage analysis, cytogenetic and
candidate gene studies helped to identify those genes. However, the high-penetrance genes
account for 5 to 10% melanoma cases, indicating that other genes, including low penetrance
genes may modulate the susceptibility. The development of new technologies has contributed
to identify new susceptible genes and understand their roles to melanoma. In this section we
discuss the “old” and the “new” genetics for melanoma susceptibility.
3.1. High penetrance genes: “The old genetics” for melanoma
3.1.1. CDKN2A – The classical susceptibility gene
The best-established gene for melanoma susceptibility is the CDKN2A (cyclin-dependent
kinase inhibitor 2A gene) locus, which is located in chromosome 9p21. Involvement of a 9p
locus in melanomas was first indicated by cytogenetically detectable loss or translocation of
this region. Subsequent loss of heterozigosity (LOH) studies and later studies indicated the
existence of a tumor suppressor gene in this region. Germline mutations in this locus have
been described among melanoma-predisposed families since 1995, and approximately 40% of
familial melanomas cases harbor CDKN2A mutations [29]. The CDKN2A locus encodes for two
different proteins, which are related to cell cycle control and tumor suppression. The two
proteins are produced by alternative reading frame of four exons [30]. The proteins produced
by CDKN2A locus, p16/Ink4a and p14/Arf, are involved with regulation of cell cycle from G1
to S phase, besides the ability of p14/Arf to induce apoptosis [30]. Regarding p16/Ink4a, its
main function is to bind to CDK4 and to inhibit its kinase activity. By inhibiting CDK4 activity,
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p16/Ink4a avoids the phosphorylation of retinoblastoma (Rb) tumor suppressor gene, acting
therefore as a negative regulator of E2F function. Thus, loss-of-function mutations or loss of
p16/Ink4a expression, allow for CDK4 to phosphorylate Rb, thereby releasing E2F activity in
the transition of G1 to S phase.
The  role  of  p14/Arf  in  tumor  suppression  is  related  to  regulation  of  p53  pathway.  Its
function  is  related  to  binding  to  HDM-2  protein  and  inhibition  of  its  activity.  The
MDM-2 protein  is  a  key regulator  of  p53 protein  due to  its  ability  to  ubiquitinate  p53,
leading  to  p53  degradation.  Thus,  by  p14/Arf  function,  MDM-2  is  depleted  and  p53  is
stabilized.  Inactivation  of  p14/Arf  functions  is  associated  with  MDM-2  accumulation,
which  in  turn  leads  to  p53  degradation  and  consequently  loss  of  its  tumor  suppressor
function. In summary, loss-of-function alterations in CDKN2A simultaneously impair two
of  the  most  critical  pathways  in  tumor  suppression,  the  Rb  and  p53  pathways.  Most
germline mutations in CDKN2A locus are missense mutations, usually found in exons 1α
and exon 2,  although mutations  in  5´  UTR and intron regions  are  also  found,  affecting
thus  translation  initiation  and  splicing  events  [31].  Overall,  CDKN2A  mutations  have
been found in 20 – 40% of families with 3 or more affected members and in 10% of fam‐
ilies with 2 melanoma cases. However the frequency can vary according to different pop‐
ulations,  fact  that  can  be  explained  by  different  founder  mutations  in  some  of  those
populations.  The  low  mutation  detection  rate  has  suggested  that  other  susceptibility
genes  exist  in  melanomas.  Moreover,  the  penetrance  of  mutations  in  CDKN2A  shows
geographical variations [32].
Some  studies  have  suggested  that  the  penetrance  of  the  CDKN2A  mutations  may  be
modulated by other genetic risk modifiers.  Certain MC1R variants (discussed below) in‐
crease  melanoma  risk  in  familial  melanomas  harboring  mutations  in  CDKN2A  [33].  As
MC1R,  a  gene  strongly  related  to  skin  color,  plays  a  role  as  a  modifier  gene,  it  seems
logical  that  other  pigmentation  genes  might  similarly  act  as  genetic  modifiers  to
CDKN2A  penetrance.  Environmental  factors,  such  as  relative  exposure  to  UV  radiation
may contribute to the variability in penetrance of CDKN2A  mutations according to geo‐
graphical reasons, as suggested by previous studies [32].
3.1.2. CDK4 – The second line in melanoma susceptibility
Another well known gene associated with melanoma susceptibility is the CDK4 gene. The gene
is located in chromosome 12q13 and codes for cyclin-dependent kinase. Mutations in the CDK4
gene were just described in 15 families with melanoma predisposition [34], where just two
known mutations are described and located in codon, Arg24Cys e Arg24His. Curiously, these
mutations can be also found in sporadic melanomas. Although less frequent than the inherit‐
able mutations in CDKN2A locus, patients harboring mutations in CDK4 usually show the
same clinical characteristics as patients with mutations in CDKN2A such as mean age at
diagnostics, mean number of melanomas and mean number of nevi [35]. These clinical
similarities (phenocopies) shown by mutations in different genes may be explained by the
same pathway that CDK4 and p16 protein share together the Rb (retinoblastoma) tumor
suppressor pathway. Both CDK4 mutant variants described above are unable to bind p16, and
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therefore CDK4 activity is not inhibited. The functional consequence is then phosphorylation
of Rb, leading to Rb inactivity and thus allowing the cell to progress on cell cycle. Only in a
few reports the whole CDK4 gene was sequenced. Expansion of CDK4 sequencing, including
the whole gene, instead of only codon 2, might help to identify new mutations in non-9p-linked
melanoma families.
3.1.3. Evidence of new susceptibility locus and other critical genes that confer risk to melanoma
Different from other familial cancer, such as breast and HNPCC colon cancers, a unique
candidate gene seems not responsible to all familial cases of melanoma. As cited above, up to
40% of familial melanomas could be attributed to CDKN2A mutations. This fact opens the
possibility to other susceptibility genes with high penetrance. A study performed in families
with no CDKN2A and CDK4 mutations identified a possible candidate locus in 1p22 chromo‐
some [36]. Subsequent analysis of this locus in additional pedigrees supported this previous
evidence. Moreover, LOH studies also indicated a putative tumor suppressor gene is this
region, however, sequence analysis has not identified any mutations [37].
Other germline mutations in critical genes responsible for cancer susceptibility, which
melanoma is not a clinically feature, also increase the risk for melanoma, where some mela‐
noma cases have been reported. Individuals harboring germline mutations in RB1 gene
(Retinoblastoma); TP53 and CHEK2 genes (Li-Fraumeni and Li-Fraumeni Like syndrome
respectively); NF1 gene (Neurofibromatosis type 1); Xeroderma Pigmentosum genes (XP) and
BRCA2 were also associated with melanoma. Even melanomas cases were reported in such
syndromes. The absolute low number of melanomas reported in these syndromes, especially
in Li-Fraumeni syndrome, creates a debate regarding whether melanomas could be a rare
manifestation of these cancer syndromes. A detailed discussion on the role of these genes and
melanoma was published elsewhere [38].
3.2. Low penetrance genes: The “new genetics” of melanoma
The great development in low penetrance genes search for melanoma risk came with the
development of genome-wide association studies (GWAS). With GWAS, several hundreds of
thousands DNA variants can be detected and larger samples sizes can be used, thus increasing
the power of analysis. A great advantage of using GWAS is the possibility to identify variants
that are not located in protein coding regions. Coupled with the development of GWAS, the
use of meta-analysis has also contributed to identify new low penetrance genes. Meta-analysis
is a widely accepted method that summarizes the results from multiple published studies, then
producing results with larger sample size and increasing statistical power. We discuss below
the main findings regarding low-penetrance genes and melanoma of GWAS and meta-analysis
studies in melanoma.
3.2.1. MC1R gene – Coloring the knowledge of melanoma susceptibility
The MC1R (melanocortin 1 receptor) is a critical gene related to human skin pigmentation.
MC1R codes for a transmembrane protein receptor that binds to α-melanocyte stimulating
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hormone (α-MSH), upon binding the activation of adenylate cyclase is triggered and conse‐
quently intracellular cAMP levels increases, then leading to a switch in melanin production
from pheomelanin pigments to eumelanin (a photoprotective pigment). The activation of
MC1R is an integral part of the tanning response following UV irradiation.
The MC1R gene is highly polymorphic, a fact that denotes the huge variation in pigmentation
phenotypes and skin colors in humans. This huge variation can create different haplotypes
(many of them with amino acid substitutions) which have been show to modify the receptor
functions altering the ratios of pheomelanin and eumelanin. The high levels of pheomelanin
associated with some MC1R variants cause the red hair and fair skin phenotype. In European
and Asian populations, there is considerable diversity of MC1R haplotypes, while in African
populations the variation is less common, indicating an evolutional pressure to keep the high
levels of eumelanin [39]. Germline variants that compromise the signaling of MC1R are present
in about 80% of red hair and fair skin individuals; about 20% in individuals with brown or
black hair and less than 4% in persons with a robust tanning response [40].
Epidemiological studies have indicated that red hair and fair skin are host characteristics
predisposing to melanoma [11]. This phenotype is known to be more sensitive to harmful
effects of UV exposure, mainly because the low capacity of tanning in red hair and fair skin
individuals. As certain MC1R variants are strongly associated with skin color, and the type of
skin color is associated with melanoma risk, it is not surprising therefore than some MC1R
polymorphisms could influence susceptibility to melanoma development. Molecular epidemi‐
ology studies have reported melanoma patients as significantly harboring some MC1R variants
more than control healthy subjects. Individuals that carry MC1R variants present a 2.2-to-3.9
fold risk to develop melanomas. Notably, there is an additive effect on having multiple
variants, for example carriers of two MC1R variants have a 4.1-to-4.8 fold risk of developing
melanoma [41-44].
In a recent meta-analysis, of 9 MC1R variants analyzed (V60L, D84E, V92M, R142H, R151C,
I155T, R160W, R163Q, D294H), all variants were associated with melanoma risk. The odds
ratio (OR) and the 95% confidence interval (95% CI), ranged from 1.18 (95% CI 1.04 – 1.35) to
V60L to 2.40 (95% CI 1.64 – 3.51) to R142H [45]. Besides the risk values, the study showed a
critical variation of a certain polymorphism among control and case populations. As example,
to V60L variant, the frequency ranged from 5% in controls to 19.75 in cases, while to R160W,
this variation was from 3.95% in controls to 11.64% in cases. The meta-analysis also validated
the risk of melanoma associated with the so-called RHC and NRHC phenotypes [45]. The RHC
phenotype (from red hair color) is defined by a nonfunctional melanocortin receptor, which
leads to accumulation of pheomelanin, phenotype associated with fair skin, red hair, freckles
and poor tanning ability [46]. Conversely, variants giving rise to receptors with a weak or
without loss of function are called NRHC (from nonred hair color) convert pheomelanin into
eumelanin less efficiently than control individuals. The RHC is composed by the variants
R151C, R160W and D294H, a dominant effect of these variants is observed and the odds ratio
to development of melanoma is 2.44 (95% CI 1.72 – 3.45) while to NRHC variants, the attributed
odds ratio is 1.29 (95% CI 1.10 – 1.51) [45].
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3.2.2. MITF
As it is well established, melanin is one of the major protective factors against ultraviolet
radiation DNA damage that results in melanoma development. The formation of this pigment
is triggered by melanocyte-stimulating hormone, a peptide hormone coded by the the
proopiomelancortin gene (POMC). Melanocyte-stimulating hormone binding to MC1R also
results in the induction of microphthalmia-associated transcription factor (MITF) [47;48]. This
transcription factor is coded by MITF gene located in chromosome 3 (3p14.2-p14.1) and it
regulates a suite of genes involved in cell cycle control and melanogenesis [49]. These functions
allow MITF to mediate differentiation and survival of melanocytes while limiting their
uncontrolled progression. It was observed by Cheli et al. (2010) [49] that loss of MITF in the
germline abolishes melanocyte formation in mice, whereas its loss in established melanocyte
gives rise to their expansion [49]. MITF achieves this partly via inducing senescence through
expression of p16INK4a, p21, and anti-apoptosis genes such as B-cell lymphoma 2 (BCL2) and
apex nuclease 1 (APEX1) [49]. Recently, two independent groups identified a rare functional
non-synonymous SNP (E318K) in MITF gene that alters MITF transcriptional activity, and it
is associated with a large population-wide melanoma risk estimated between odds ratio 2.19
(95% CI 1.41, 3.45) and 4.78 (95% CI 2.05, 11.75) ([50],[51]; respectively). MITF gene is also
associated with increased nevus count and non-blue eye color, consistent with its enhanced
transcriptional ability. Adjusting for these traits reduced (odds ratio 1.82, 95% CI 0.85, 3.92)
but did not abolish E318K association with melanoma [50].
There is a positive feedback loop in melanocytes caused by UV radiation damage, which
increases  melanin  production  and  blocks  cell  cycle  progression  via  MITF  until  DNA
damage  is  no  longer  detected  [48].  Given  its  protective  nature,  melanoma  researchers
have spent significant effort testing skin coloration genes derived from animal studies or
genetic  association  studies  identified  as  targets  of  MITF,  or  highlighted  by  human pig‐
mentation GWAS [52;53].
3.2.3. Other pigmentation genes
SLC45A2
Genetic epidemiological studies have recently identified a subset of other pigmentation genes
that are associated with risk for melanoma and other cutaneous malignancies as well as
photosensitivity for MITF-regulated solute carrier family 45 member 2 gene - SLC45A2 [54;55].
This gene is located in chromosome 5p, comprised of seven exons spanning 40 kb, and encodes
a 530 amino acid protein presumably located in the melanosome membrane [56-57]. The
protein SLC45A2 probably directs the traffic of melanosomal proteins and other substances to
the melanosomes [57]. The mutation 1122C>G in SLC45A2gene, which results in non-synon‐
ymous amino acid change (Phe374Leu) has been related with pigmentation variation and
ethnic ancestry in different populations [58]. However, according to meta-analysis that
summarize some association studies [54;55], this mutation confers protection from cutaneous
melanoma in individuals with a fair phenotype in populations from South European regions
(France, Italy and Spain) – OR =0.41 (95% CI: 0.33–0.50). This meta-analysis may explain the
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incidence of melanoma in cases with skin phototypes III–IV, dark eye and hair color, absence
of ephelides, lentigines and with a low number of nevi [57].
ASIP
Another pigmentation gene extensively studied in melanoma is ASIP, located in chromosome
20q11.22, which encodes agouti signaling protein. Agouti signalling protein (ASIP) was first
described to inhibit eumelanogenesis in human melanocytes [59]. The protein ASIP is a MC1R
ligand of 132 amino acids that antagonises the function of the transmembrane receptor [60].
According with a recent review [34], in a large study of European population descendants, a
significant association was found between two SNP haplotype (rs1015362 and rs4911414), at
the ASIP locus and cutaneous melanoma, with a modest OR =1.45 [61]. In another study [62],
the haplotype near ASIP with same SNPs was associated with fair skin color (OR, 2.28; 95%
CI, 1.46-3.57) as well as the risks of melanoma (OR 1.68; 95% CI 1.18-2.39). Similar results were
described [63] in a German population study with increased risk to melanoma development
in carriers of the rs4911414 variant (OR 1.27; 95% CI 1.03–1.57). An Australian genome-wide
association study [64] also indicated the presence of a melanoma susceptibility locus on
chromosome 20q11.22, with an OR of 1.72 for ASIP SNPs, (rs910873 and rs1885120). As the
ASIP gene encodes the antagonist melanocortin receptor, polymorphisms of this gene can alter
the protein conformation or decreased level of ASIP mRNA in melanocytes. As a consequence
of low ASIP protein levels, its inhibiting effect is diminished, while eumelanogenesis is
increased. If there are some altered ratio of pheomelanin and eumelanin caused by huge
variation in MC1R gene, the high level of pheomelanin synthesis will increase, resulting in
phenotypes with increased risk of cutaneous melanoma (red hair and fair skin phenotype).
TYR
The gene TYR, located in 11q14-q21, coded tyrosinase, which is a copper-dependent enzyme
that catalyzes the first two steps during melanogenesis. The protein is required for the
synthesis of both types of melanin, eumelanin and pheomelanin. While a basal activity of the
enzyme leads to pheomelanin synthesis, a switch to eumelanogensis occurs upon increased
protein activity. It has been reported that TYR presents higher enzymatic activity in a neutral
environment than in acidic conditions. This formed the basis for the assumption that a neutral
environment is required for the formation of eumelanosomes instead of pheomelanosomes
and that the pH value is a control mechanism for melanin synthesis [65]. In a recent review of
the literature [34] polymorphisms in TYR gene has also been implicated in cutaneous malig‐
nant melanoma susceptibility, where variants in coding region (rs1126809) of the gene
increased melanoma risk (OR 1.27; 95% CI 1.16: 1.40 and OR 1.22 ; 95% CI 1.14 : 1.31) ([66]
[67]; respectively).
Genome-wide association studies (GWAS) have unveiled single nucleotide polymorphisms
(SNPs) or genetic variants in other genes involved with pigmentation pathways that can
contribute to melanoma susceptibility. Examples follow; two pore segment channel 2
(TPCN2), KIT ligand (KITLG), solute carrier family 24, member 5 (SLC24A5), interferon
regulatory factor 4 (IRF4), oculocutaneous albinism II (OCA2), HECT and RLD domain
containing E3 ubiquitin protein ligase 2 (HERC2) and tyrosinase-related protein 1 (TYRP1)
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pigmentation genes. These findings emphasize the contribution of pigmentation pathways to
melanoma predisposition and tumorigenesis through gene-environment interactions. Since
pigmentation genes in the melanin synthesis pathway also confer risk for cutaneous malig‐
nancy, a better understanding of the operative molecular mechanisms involved in this
relationship has the potential to impact individual risk assessment for cutaneous malignant
melanoma in the future [68].
3.2.4. DNA repair genes – Polymorphisms contributing to a mutator phenotype?
Epidemiological and experimental data suggest that UV radiation is the main carcinogenic
agent responsible for melanoma development. While UV-B radiation (290–320 nm) induces
critical damage to DNA in the form of cyclobutane pyrimidine dimers (CPD) and pyrimidine
photoproducts, UV-A radiation (320–400 nm) induces single strand breaks and generates free
radicals that cause oxidative damage [69]. While UV-induced DNA damage often activates
distinct DNA repair pathways that maintain genome integrity, the main processes involve the
Base Excision Repair (BER), which operates mainly to repair damage caused by oxidative stress
and single strand breaks and Nucleotide Excision Repair (NER) that acts to neutralize
photoproducts such as CPD and 6–4 dimers [2].
The differences in DNA repair capacity among individuals are genetically determined in
function of  mutations and polymorphisms in many genes implicated in these pathways
and it has been examined in relation to cutaneous malignant melanoma. According with
a  recent  review  [34],  some  studies  found  significant  association  between  variations  in
DNA  repair  genes  and  melanoma.  The  gene  XPD,  located  in  19q13.3,  codes  a  protein
that  is  involved  in  transcription-coupled  nucleotide  excision  repair  and  is  an  integral
member  of  the  basal  transcription  factor  BTF2/TFIIH  complex.  The  SNP  13181  A>C  in
exon 23 of the gene, with amino acid change in protein (Lys751Gln) was described as a
risk factor for cutaneous melanoma susceptibility, with an OR of 1.12 (95% CI, 1.03-1.21)
[70]. Other polymorphisms in members of XP family genes involved with NER pathway
were  also  described.  Another  recent  study  found  melanoma  protection  for  the  XPG
(13q33)  1104 His/His  genotype (OR 0.32;  95% CI 0.13-0.75),  and increased risk for  three
polymorphisms  in  chromosome  3p25  at  XPC  gene  (OR  3.64;  95%  CI  1.77-7.48)  (PAT+;
IV-6A and 939Gln), which represent a haplotype for XPC [71].
In other repair pathways significant association has been described, for example variants in
exon 7 of XRCC3 (14q32.3). This gene encodes a member of the RecA/Rad51-related protein
family that participates in homologous recombination to maintain chromosome stability and
repair DNA damage. T241M XRCC3 was associated with an increased risk for cutaneous
melanoma [72]. Individuals who carry variant alleles had a decreased risk of cutaneous
melanoma (OR 0.83, 95% CI, 0.79-0.98) [72]. Same results were found in a previous study [73].
An additional study reported a significant association between MGMT haplotypes and
cutaneous melanoma risk, with a greater risk observed among 84Phe or 143Val carriers, who
have a lower alkylation-damage repair capacity due to the variant alleles [74].
A summary of the main founds regarding low penetrance genes and melanoma risk can be
found in Table 1.
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Gene/ Polymorphism rs OR (95% CI) References
MC1R - V60L 1805005 1.10 (1.04-1.35) [45]
MC1R - D84E 1805006 1.67 (1.21-2.30) [45]
MC1R - V92M 2228479 1.32 (1.04-1.68) [45]
MC1R - R142H 11547464 2.40 (1.64-3.51) [45]
MC1R - R151C 1805007 1.93 (1.54-2.41) [45]
MC1R - I155T 1110400 1.39 (1.05-1.83) [45]
MC1R - R160W 1805008 1.55 (1.21-1.97) [45]
MC1R - R163Q 885479 1.21 (1.02-1.42) [45]
MC1R - D294H 1805009 1.89 (1.39-2.56) [45]
MITF - E318K 149617956 2.19 (1.41-3.45)4.78 (2.05-11.75)
[50]
[51]
SLC45A2 - F374L 16891982 0.41 (0.33-0.50) [57]
ASIP - haplotype G;T 1015362/4911414
1.45 (P = 1.2 x 10-9)
1.68 (1.18-2.39)
1.27 (1.03-1.57)
[61]
[62]
[63]
ASIP - haplotype G;G 910873/ 1885120 1.72 (1.53, 2.01) [64]
TYR - R402Q 1126809 1.27 (1.16-1.40)1.22 (1.14-1.31)
[66]
[67]
XPD - K751Q 1052559 1.12 (1.03-1.21) [70]
XPG - D1104H 17655 0.32 (0.13-0.75) [71]
XPC - IV11-6C/A 3.10 (1.65–5.83) [71]
XPC - K939Q 2228001 2.89 (1.52–5.50) [71]
XPC - PAT(-/+) 3.27 (1.75–6.12) [71]
XPC haplotype
PAT+; 6A,Gln allele 3.64 (1.77–7.48) [71]
XRCC3 - T241M 861539 0.83 (0.79-0.98)2.36 (1.44–3.86)
[72]
[73]
MGMT haplotype
L84F/ I143V
12917/
2308321 1.75 (1.11-2.76) [74]
Table 1. Summary of low-penetrance candidate melanoma susceptibility genes
4. Melanoma genetics: Progression genes
4.1. “Old genetics” of melanoma progression
The here called “old-genetics” of melanoma progression consist of known genes which its
functions are well described and are also related to several other cancer types, mainly due to
its function in controlling survival and proliferation pathways. An overview of such “old-
genetics” of melanoma is shown in Figure 1.
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Figure 1. A schematic view of the main genes and pathways related to melanoma progression. The genes and path‐
ways described are the here called “old genetics” of melanoma progression. Arrows indicate activation and blunt ar‐
rows indicate inhibition.
4.1.1. Mitogen-Activated Protein Kinases (MAPK) pathway – MAPing the first melanoma progression
pathway
Several molecular pathways are activated/deactivated during tumor formation and some of
them are responsible for the development of specific phases of tumor progression. Among
them, is the Mitogen-activated protein kinases (MAPK) pathway. The pathway consists in a
chain-like activation cascade of serine/threonine-specific protein kinases, where one protein
must be phosphorylated to activate another. The proteins involved in this pathway are the
RAS oncogene, discovered in the early 80s, with three known isoforms (H-Ras, K-RAS and N-
RAS); RAF kinase, with also three isoforms (A-RAF, B-RAF and C-RAF or RAF-1); MEK kinase
and ERK kinase, which have cytoplasmic targets or can phosphorylate transcription factors in
the nucleus. The MAPK pathway is one of the most well-known pathways involved not only
in melanoma formation, but probably in most types of tumors. The pathway is responsible to
conduct an extracellular signal, like growth signal, from receptors in cell surface towards cell
nucleus. After activation of RAS, the first protein of the cascade, a multitude of cellular
responses, like protein synthesis, regulation of cell survival, differentiation and proliferation
can be observed, showing the importance of this pathway for melanoma progression. Muta‐
tions in MAPK pathway are necessary for the development of early stages melanomas, as the
transfection of constitutively activated MEK into immortalized melanocytes is sufficient to
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induce tumorigenesis in nude mice, activation of the angiogenic switch, and increased
production of the pro-angiogenic factor, vascular endothelial growth factor (VEGF), and
matrix metalloproteinases (MMPs) [75].
The most common mutations found in MAPK proteins in melanomas are in RAS protein, more
specific in N-RAS and in RAF proteins, in B-RAF. The RAS proteins are members of a large
superfamily of low molecular-weight GTP-binding proteins. The activation state of RAS
proteins depends on whether they are bound to GTP (in which case, they are active and are
able to engage downstream target enzyme) or GDP (in which case, they are inactive and fail
to interact with these effectors). In normal cells, the activity of RAS proteins is controlled by
the ratio of bound GTP to GDP [76]. N-RAS mutations can be found in over 15% of all
melanoma cases and are most commonly the result of the substitution from leucine to
glutamine at position 61 [77]. It is correlated to the vertical growth phase of melanoma
progression. Although initially thought to occur mainly at the plasma membrane, there is
increasing evidence that isoform-specific RAS signaling can take place at different cellular
compartments and within different regions of the plasma membrane. Such compartmentali‐
zation and trafficking of endogenous RAS oncogenes is likely to play an important role in
regulating downstream signaling processes involved in tumorigenesis [78]. For its activation
and function as a signal transducer, N-RAS needs to be modified by a farnesylation near its C-
terminal domain. Several farnesylation inhibitors were tested in the clinics and all results were
disappointing [79]. In part, the failure of the clinical trials can be explained due to the fact that
the farnesylation inhibitors may work in Rho (a subfamily of RAS superfamily) rather than
RAS, or the fact that the inhibitors works on normal and mutated RAS.
Other important component of MAPK pathway that is mutated in melanomas is the RAF
kinase B-RAF, the primer mediator of RAS protein. Some reports have shown that over 60%
of all melanoma cases have mutation in B-RAF [80]. RAF mutations occur in the kinase domains
and the most common mutation found in melanomas, approximately 80%, is the substitution
of valine at position 600 with glutamic acid also called B-RAFV600E mutation. This mutation
creates a constitutively active status for B-RAF, independently of a previous activation by RAS
oncogene and extracellular stimulus and it is more frequently found in skin of individuals with
intermittent sun exposure than unexposed or chronically sun-damaged skin. Interestingly, B-
RAF mutation frequency in benign melanocytic nevi seems to be equal or even higher than in
that for melanomas. The frequency also varies, like melanomas, from 0% in Spitz nevi up to
90% in intradermal nevi. These differences, between B-RAF mutation in nevi and melanomas
make the assessment of the impact of these mutations on prognosis difficult to determine [38].
B-RAF mutation in nevi might be a critical step in melanoma development, suggesting its
importance in early stages of the disease.
Melanomas  usually  do  not  have  B-RafV600E  mutation  at  the  same time  they  have  muta‐
tions  in  any RAS isotype.  However,  some small  proportions  of  cases  carry mutation in
both B-RAF and any RAS isoform, but in these cases, B-RAF mutation almost never is in
V600E locus  [81].  Recently,  a  link  between B-RAF and the  cell  cycle  controller  E2F has
been shown. B-RAF is able to phosphorylate the retinoblastoma (Rb) protein and release
E2F transcription factor family to work [82].  E2F family is  a classic cell  cycle controller,
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but  can  also  induce  DNA  repair,  regulates  autophagy  and  MMPs  expression.  The  link
between MAPK pathway and E2F transcription factor family may provide new strategies
for melanoma treatment. New drugs using the B-RafV600E  mutation as a target is current‐
ly being used in the clinics.  Vemurafenib (PLX-4032) is  a novel  treatment for metastatic
disease for melanomas with the V600E mutation. Vemurafenib treatment has demonstrat‐
ed  improved  progression-free  and  prolonging  overall  survival  in  three  months,  com‐
pared with chemotherapy in a randomized trial,  and represents a new standard of  care
in  patients  with  advanced  melanoma  harboring  a  BRAF-V600  mutation  [83].  However,
Vemurafenib treatment induces several  resistance pathways in B-RafV600E  cells  and is  ex‐
pected to failure after a few months, but it is the best treatment for melanoma disease so
far. Among the resistance pathway induced by the drug are MEK activation by MAP3K8
[84],  up  regulation  of  N-RAS [85]  and  activation  of  fibroblast  growth  factor  receptor  3
(FGFR3) [86].
4.1.2. PI3K pathway – Supporting MAPK pathway to melanoma progression
RAS can also activate other effectors pathways rather than RAF. RAS can interact directly with
phosphatidylinositol 3-kinases (PI3Ks), activating other molecular pathways. One of the
pathways activated by PI3Ks is the AKT/PKB pathway, which has a strong anti-apoptotic
function by phosphorylating various targets and seems to be an important part of the survival
signal that is generated by RAS activation.
MAPK activation is necessary for early stages melanomas, but is not sufficient for the devel‐
opment of advanced disease. Other molecular mechanisms are necessary for melanoma invade
other tissues and survive in different microenvironments. AKT/PKB seems to be important for
the development of radial growth melanomas, from cell lines which are characterized as radial
growth melanomas. In this model, AKT overexpression induced VEGF expression and
switched to a more glycolytic metabolism [87]. The AKT family consists of three members,
AKT1–3 and 43–50% of melanomas have a selective constitutively active AKT3. AKT3
overexpression may occur as a result of copy number increases in the long arm of chromosome
1. Another mechanism for PI3K/AKT pathway activation in melanoma is through the acquis‐
ition of activating E17K mutations in AKT3. AKT has a critical role in cancer development
through its ability to block apoptosis through the direct phosphorylation of BAD as well as
through its effects in many other pathways, including the inhibition of forkhead signaling and
the inhibition of glycogen synthase kinase-3. One of the most critical regulators of AKT is the
phosphatase and tensin homolog (PTEN), which degrades the products of PI3K, preventing
AKT activation. The mechanism by which the PI3K/AKT pathway is activated in melanoma
may involve the loss of expression or functional inactivation of PTEN [88]. However, PI3K
pathway mutations, though more heterogeneous, were present in 41% of the melanoma, with
PTEN being the highest mutated gene of the PI3K pathway in melanomas (22%) [89].
PTEN is a tumor suppressor gene located in chromosome 10q23.3 and is a dual specificity
phosphatase capable of dephosphorylating both tyrosine phosphate and serine/threonine
phosphate residues in proteins. It also functions as a major lipid phosphatase, counteracting
PI3K by dephosphorylating the second messengers phosphatidylinositol-3,4,5-triphosphate
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(PIP3) and phosphatidylinositol-3,4-diphosphate (PIP2), which are required for the activation
of AKT/PKB [17]. PTEN can work in other pathways than AKT/PKB. PTEN is involved in cell
migration, spreading, and focal adhesion formation through direct dephosphorylation and
inactivation of focal adhesion kinase (FAK). Also, PTEN inhibits Shc phosphorylation,
preventing the association of Shc with Grb2/Sos and activation of the Ras/Raf/MEK1/MAPK
pathway. PTEN suppresses the stabilization of hypoxia-mediated HIF-1α, which when
stabilized through the PI3K/AKT pathway, upregulates VEGF expression suggesting a
possible role for PTEN in angiogenesis [88]. An interesting study sequenced the PTEN gene
from melanomas from patients harboring the Xeroderma Pigmentosum syndrome [90]. A total
of 59 melanomas from 8 XP patients showed a mutation rate of 56% in PTEN gene. A detailed
look for the mutational spectrum revealed that 91% of the melanomas with mutations had 1
to 4 UV type mutations (C to T changes) occurring at adjacent pyrimidines. Functional analyses
also indicated impared PTEN function caused by the mutations. The study showed critical
data to the understanding of melanoma progression in XP patients.
4.1.3. WNT5A – Progression to the edges, leading to melanoma metastasis
The metastatic disease does not have fixed histopathological subclasses. That is why there is
a need to look for genetic profiles that could predict a behavior in advanced stages. WNT5A,
a protein of Wnt family, was identified as the gene that best defined the new subclasses of
tumors. The Wnt family of proteins has over 19 members, all of which are secreted, that are
very closely structurally related. The activation of Wnt signaling can have very different results
depending on which members of the family are involved. Wnt proteins work through three
different pathways: the β-catenin pathway, the Wnt/Ca2+ pathway and the planar cell polarity
pathway. The activation of WNT5A in melanomas uses the non-canonical pathway Wnt/Ca2+
together with Frizzled receptors, activating phospholipase C, which translocate to the
membrane and hydrolyzes membrane phospholipids, initiating phosphatidylinositol signal‐
ing [91]. In vitro analysis of melanoma cell lines differing in WNT5A expression levels showed
that WNT5A overexpression is correlated with increased motility and invasiveness of the cell
[91]. WNT5A correlates with high aggressive metastatic disease and its activation is mediated
through PKC pathways which are associated to cytoskeletal organization and invasion.
WNT5A protein expression in human melanoma biopsies directly correlates with increasing
tumor grade while inversely correlating with patient survival [92]. Members of the Wnt
pathways have been identified in melanoma. WNT5A and others members like Rho pathway
and frizzled 7 may play an important role in transition of melanoma from VGP to metastases.
It is very likely that the temporal activation of Wnt pathways is very important for melanoma
development and progression. It would not be surprising if β-catenin expression was an early
event, and metastatic cells need to down regulate expression of this protein prior to invading,
and escaping the immune system. WNT5A may provide a survival advantage to melanoma
cells, despite the fact that in others tumor it may act as a tumor suppressor. Thus, its early
expression may result in suppression of tumorigenesis, whereas if it is expressed at a later
stage, it becomes a potent inducer of migration and motility. Wnt signaling and its effects on
melanoma establishment and progression are complex, and surely temporal and context
dependent [92].
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4.2. “New genetics” of melanoma progression
Melanoma is a complex genetic disease. Recent studies have begun to characterize the
mechanisms underlying melanoma plasticity, relating to intratumoral switching between
varying malignant capacities, such as proliferation, invasion, or tumorigenesis. The rate at
which somatic and germline genetic alterations have been cataloged in melanoma has
accelerated greatly in recent years. The ability to modulate genes and proteins of interest, even
when pharmacologic agents are not available, has provided preclinical evidence that many
putative oncogenes represent potential therapeutic targets [93]. At the same time, the notorious
resistance of melanoma to treatments with its strong potential to metastasize represents the
major clinical obstacle in the treatment of these tumors. These observations allow the scientists
to improve staging and subtype classification and lead them to design better therapeutic agents
and approaches. New insights about genetics of melanoma, including high-throughput
strategies such as gene expression microarrays, comparative genomic hybridization, mutation
analysis by deep sequencing and microRNAs gene regulation have helped researchers to
elucidate the crucial cell-signaling pathways or validate the already postulated pathways as
modified in melanomas. The genes and pathways discussed below for the “new genetics” of
melanoma progression are represented in Figure 2.
Figure 2. A schematic view of the main genes and pathways related to melanoma progression. The genes and path‐
ways described are the here called “new genetics” of melanoma progression. Arrows indicate activation and blunt ar‐
rows indicate inhibition.
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4.2.1. Activating Transcription Factor 2 (ATF2) – Helping melanoma progression activation
The ATF2 (Activating Transcription Factor-2 or cAMP response element [CRE]) it was first
identified as an inducible enhancer of genes that can be transcribed in response to increased
cAMP levels and mediates various transcriptional regulatory effects, for example, ATF2/Jun
complex is implicated in multiple cellular processes [94,95]. The ATF2 transcriptional targets
genes is divided into (a) regulation of transcription factors and proteins engaged in stress and
DNA damage response (b) regulation of genes associated with growth and tumorigenesis (c)
regulation of genes important for maintenance and physiological homeostasis [94]. In addition
to its function as a transcription factor, ATF2 was found to play an important role in DNA
damage response. After damage occurs, ATF2 is phosphorylated by ATM and its results in
rapid localization of ATF2 to ionizing radiation (IR) induced foci (IRIF), which contain DNA
repair proteins and chromatin-modifying enzymes. Furthermore, ATF2 phosphorylated is
required for an intact intra-S-phase checkpoint response necessary to stop DNA replication
[96]. In recent years, the study of ATF2 activity in melanoma cells has revealed a probably
oncogenic function. In the early '90s, Ronai and Weinstein [97] elucidated the cellular response
to UV irradiation. The authors characterized a UV-responsive element (URE;TGACAACA)
and soon after, its binding proteins, AP1 and ATF family members [98]. Interesting, the URE
was found within the promoter sequences of stress-responsive genes, including c-jun, DNA
polymerase B, and cyclin A, as well as on regulatory regions of viruses that respond to UV
irradiation [99]. Differences in transcriptional activities of URE-bound proteins were found
after UV-irradiation of keratinocytes, melanocytes and melanoma, and also in repair deficient
cells of patients with Xeroderma pigmentosum, or Cockayne syndrome [for review 9]. In 1998,
the Ronai´s group investigated which of the CREB-associated proteins is directly involved in
modifying specific characteristics of melanoma phenotypes. They demonstrate that ATF2 is
the primary binding protein and regulator of URE-mediated transcription and it contributes
specifically to radiation resistance of human melanoma cells.
An approach to selectively inhibit ATF2 activity in human melanoma was designed, based on
peptides derived from ATF2 trans-activating domain which affect ATF2 transcriptional
activity. In an attempt to sensitize melanoma cells to UV irradiation, Ronai et al. investigated
the ability of cells to enter in apoptosis competing by endogenous ATF2 expression with ATF2-
derived peptide(s) alone and/or combined with inhibition of p38 activity (one Mitogen-
activated Protein Kinases that is responsive to stress stimuli) via its pharmacological inhibitor
(SB203580) [100]. The expression of a 50-amino acid peptide derived from the NH2-terminal
domain of ATF2 (ATF250–100) was sufficient to sensitize melanoma cells to radiation. Combi‐
nation of this peptide with SB203580 induced programmed cell death in late stage melanoma
cells via Fas signaling, whereas Fas ligand/receptor interactions play an important role in the
progression of cancer. In 2002, experimental mouse models validated the expression of this
peptide. The ATF250–100 not only sensitized melanoma cells to apoptosis but efficiently inhibited
tumor growth and metastasis [101]. Analysis of mouse cell lines derived from melanomas
formed in the HGF/SF (Hepatocyte Growth Factor/Scatter Factor) transgenic mouse, revealed
that the proliferation rate in culture increased with increased ATF-2 activity [102], confirming
the role of ATF2 in melanoma development. Along these lines, B16 mouse melanoma cells
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exhibit higher levels of phosphorylated ATF2 compared to immortalized non-malignant
mouse melanocytes. Following treatment with retinoic acid, ATF2 phosphorylation was
reduced, resulting in c-Jun dimerization with c-Fos and promoting a shift from proliferation
towards differentiation [103]. Additional experiments showed that delivery of ATF2 inhibitory
peptides elicited efficient inhibition of melanoma tumor growth [104].
Even with these encouraging results, one question remains unanswered: how ATF2 inhibition
induces apoptosis in melanoma cells? It was demonstrated that ATF250–100 induced apoptosis
by sequestering ATF2 to the cytoplasm, thereby inhibiting its transcriptional activities [105].
In addition, mutations within the c-Jun N-terminal kinases (JNK) binding region of ATF250–
100 or expression of TAM67, a dominant negative of the Jun family of transcription factors, or
JunD-RNA interference attenuate inhibition of melanoma tumorigenicity by ATF250–100. The
JNKs are kinases responsive to stress stimuli, such as ultraviolet irradiation used in this study.
These results were crucial to show that inhibition of ATF2 in concert with increased JNK/Jun
activities is central for the sensitization of melanoma cells to apoptosis and inhibition of their
tumorigenicity. Furthermore, ATF250–100 increases ATF2 localization within the cytoplasm.
Indeed, one study evaluating the ATF2 as a prognostic marker among patients with melano‐
mas validated this result. A study to determine the prognostic value of ATF2 evaluating the
pattern and level of its expression in a tissue microarray was conducted [106]. Cytoplasmic
ATF2 expression was associated with primary tumor rather than metastases and with better
patient survival whereas nuclear ATF2 expression was associated with metastatic tumor and
with poor survival. Nuclear ATF2 seems to be transcriptionally active while cytoplasmic ATF2
probably represents an inactive form. These findings support one preclinical finding in which
transcriptionally active ATF2 is involved in tumor progression-proliferation in melanoma,
suggesting that ATF2 might be a useful prognostic marker in early-stage melanoma. Although
the use peptide ATF250–100 have shown good results to sensitize melanoma cells to treatments,
Ronai group´s continued investigating peptides with smaller size but producing the same
effect. In 2004, Bhoumik et al. [107] presented one peptide with only 10aa - ATF251-60. This
peptide sensitizes melanoma cells to spontaneous apoptosis and inhibits the in vivo growth.
Furthermore, the ATF251-60 expression coincides with activation of caspase 9, an important
molecule activated during apoptosis. This study points to mechanisms underlying the
activities of the ATF2 peptide while highlighting its possible use in drug design.
Based on these findings, ATF2 present oncogenic action, but could it act as one tumor sup‐
pressor molecule? Although genetic changes in ATF2 have not been identified in human
tumors, many data sustain the notion that ATF2 is not only oncogenic, whereas its altered
expression and sub cellular localization is associated with tumor stage and prognosis in
melanomas, but it also acts as a tumor suppressor molecule, under specific conditions. This
hypothesis arose from independent studies with skin and mammary tumors. Studies from a
mouse mammary tumor model revealed that loss of ATF2 per se, does not promote mammary
tumor formation, but heterozygous mouse ATF2 mutants developed mammary tumors when
crossed with p53 mutant mice, indicating that ATF2 may have a suppressor function only when
combined with a p53 mutant background [108]. Likewise, loss of ATF2 transcriptional
activities in keratinocytes promotes faster development of skin papillomas. Deletion of
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functional ATF2 in keratinocytes was achieved using a K14-cre mouse which was crossed with
mutant ATF2 mice. Exposure of K14-ATF2 mutant mice to DMBA (a carcinogen that causes
Ras mutation) followed by application of TPA (a tumor promoter) resulted in faster formation
of papillomas which were bigger, compared with mice bearing wild-type (WT) ATF2 in their
keratinocytes [109]. Importantly, mice in which ATF2 was deleted only in keratinocytes did
not develop papillomas, differently from WT mice when treated with the carcinogens DMBA
or TPA alone. Therefore, ATF2 can limit tumor development by cooperating with existing
oncogenes and inactivated tumor suppressor genes.
Present knowledge positions ATF2 as important transcription factor and DNA damage
response protein, which is also implicated in the regulation of cellular growth control. Along
the growing complexity of understanding ATF2 regulation and function are the observations
that point to its ability to elicit oncogenes or tumor suppressor functions, depending on the
tissue type. Based on these findings, it was proposed one model for ATF2 oncogenic versus
tumor suppressor functions. Future studies will reveal the nature of these major differences,
and further delineate the important role ATF2 plays in cellular growth control prior and
following DNA damage, as in transformation and cancer development. In addition, the ATF2
function findings highlight the importance of transcriptional regulation, which enables the
sensitization of melanoma to treatment and inhibits their growth and metastasis in vivo.
4.2.2. Microphthalmia-associated Transcription Factor (MITF) the conductor of melanoma players
Microphthalmia locus displays important roles for biology and pathology of pigmentation of
the skin, as well as eye development and degeneration. Ever since, many other mutant alleles
of the locus have been found in mice and other vertebrates [for review 110].The human MITF
gene (3p14.2-p14.1) was cloned in 1994 [111] and so far, MITF-A, MITF-B, MITF-H, and MITF-
M splice variants were described [112;113]. MITF contains a basic DNA binding domain and
binds to DNA sequences primarily consisting of a 5´-CATGTG-3´ or 5´-CACGTG-3´ motif
[114-116]. Ten isoforms of MITF have been described [117], but the m-MITF isoform is
exclusively expressed in melanocytes. All MITF isoforms have a central transcriptional
activation domain. MITF acts as a transcription factor which controls proliferation and
apoptosis and plays a central role in the differentiation, growth, and survival of cells of the
melanocytic lineage [118]. MITF is the main transcription activator for key genes involved in
melanogenesis (TYR, TYRP1, MLANA, SILV), but its function can switch, in balance with
POU3F2, to activate proliferation and inhibit invasion [119].
Recent  observations of  reversible  phenotypic  heterogeneity  in melanoma have proposed
a novel  “phenotypic  plasticity  model”  of  cancer,  whereas  MITF seems to  be  one of  the
central  players  in  melanoma phenotypic  plasticity.  The  “dynamic  epigenetic  model”  or
rheostat  model  proposes that  variations in the tumor microenvironment result  in epige‐
netic lesions, leading to alterations observed in melanomas [for review 120]. In this mod‐
el,  high expression levels  of  MITF regulate  genes  involved with  differentiation and cell
cycle arrest. When MITF is expressed at average levels, melanoma cells proceed through
cell  cycle,  while  reduction of  MITF to  low levels  switches off  the cell  proliferation pro‐
gram,  inducing  cell  cycle  arrest,  and  promotes  invasion  and  metastasis.  For  example,
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prolonged MITF depletion leads melanomas to either quiescence or senescence [121]. So,
MITF  regulates  distinct  functions  in  melanocytic  cells  at  different  levels  of  expression.
While MITF lower levels are commonly observed in melanoma cells rather than in mela‐
nocytes,  high  levels  of  MITF  activate  the  expression  of  differentiation-associated  genes
implicated  on  melanosome  function  and  promote  a  differentiation-associated  cell  cycle
arrest via up regulation of the p16 (CDKN2A)  and p21 (CDKN1A)  cyclin-dependent kin‐
ase  inhibitors  ([122-124].  Chromatin  immunoprecipitation  of  MITF  from  501  melanoma
cell line followed by high-throughput deep sequencing and RNA sequencing from MITF-
depleted  cells,  showed  TYROSINASE,  MET,  LIG1,  BRCA1,  CCND1,  and  CCNB1  genes
transcriptionally-regulated by MITF. Thus, MITF-depleted cells exhibit diminished capaci‐
ty to passage through S-phase and repair DNA damage. These data highlight the multi-
tasking  role  of  MITF  that,  in  addition  to  differentiation,  survival,  and  its  anti-
proliferative roles, also includes a role in the S phase, controling mitosis and suppressing
senescence.  In  an  opposite  way,  increased  MITF levels  reduce  melanoma cell  prolifera‐
tion even in the presence of oncogenic BRAF [124]. MITF can cooperate with BRafV600E to
transform immortalized melanocytes by expression of telomerase (TERT), dominant-nega‐
tive p53 and activated Cdk4 [121]. These data indicates that, although MITF alone cannot
transform normal human melanocytes, it can cooperate with BRafV600E to contribute to the
transformation process,  functioning as a “lineage-specific oncogene”, because it  provides
essential  survival  functions and contributes to proliferation.  In this  context,  and bearing
in mind that ERK is hyperactivated in melanoma and required for proliferation and sur‐
vival,  it  is  striking  that  MITF  is  targeted  for  degradation  after  its  phosphorylation  by
ERK [125].  Indeed,  constitutive  activation of  ERK by BRafV600E  in  melanocytes  results  in
constant down regulation of MITF [for review 126].
One interesting example from different levels of MITF action came from an elegant transla‐
tional study [127]. The authors demonstrated that the transcription factor ATF2 negatively
regulates MITF transcription in melanocytes and around 50% of melanoma cells. Increased
MITF expression (upon inhibition of ATF2), effectively attenuated the ability of BRafV600E-
melanocytes to exhibit a transformed phenotype. This effect was partially rescued when MITF
expression was also blocked. The development of melanoma in mice carrying genetic changes
seen in human tumors was inhibited upon inactivation of ATF2 in melanocytes. Melanocytes
from mice lacking active ATF2 increased levels of MITF, confirming that ATF2 negatively
regulates MITF and implicating this newly discovered regulatory link in melanomagenesis.
Additionally, primary melanoma specimens that exhibit a high nuclear ATF2-to-MITF ratio
were found to be associated with metastatic disease and poor prognosis, substantiating the
significance of MITF control by ATF2. Taken together, these findings provide a genetic
evidence for the role of ATF2 in melanoma development and indicate an ATF2 function as a
regulator of MITF expression, which is central to understanding MITF control at the early
phases of melanocyte transformation.
Another  possible  mechanism  that  could  explain  the  different  levels  of  expression  of
MITF  observed in melanoma cells is DNA copy number alterations (CNAs). Copy num‐
ber  alterations  involving  “driver  genes”  can  modulate  substantially  their  expression
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[128].  Melanoma genomes  frequently  contain  somatic  copy  number  alterations  that  can
significantly  perturb  the  expression level  of  affected genes.  Recently,  accurate  strategies
have been used to identify new genes and/or focus on molecular  pathways already de‐
scribed as affected in melanomas (BRAF,  PTEN  and MITF  alterations) [129]. By using in‐
tegrative  strategy  of  SNP (Single  Nucleotide  Polymorphism)  array-based genetic,  which
has  higher  genomic  resolution  than  CGH  arrays,  with  gene  expression  signatures  de‐
rived from NCI60 cell  lines identified MITF  as  the target  of  novel  melanoma amplifica‐
tion  [121].  MITF  amplification  was  more  prevalent  in  metastatic  disease  and  correlated
with decreased overall patient survival. BRAF mutation and p16 inactivation was accom‐
panied by MITF amplification in melanoma cell lines. Moreover, it was described that ec‐
topic  MITF  expression  in  conjunction  with  the  BRAFV600E  mutant  transformed  primary
human melanocytes, reinforcing the MITF as a melanoma oncogene. Although MITF am‐
plification  (10–100-fold)  is  observed  around 10–16% of  metastatic  melanomas  (in  which
BRAF  is  mutated),  MITF  levels  are  only  increased  about  1.5-fold  compared  with  cells
without amplification [121], again suggesting that MITF levels must be maintained with‐
in  narrow  limits.  However,  because  only  10–16%  of  BRAF-mutated  melanomas  have
MITF  amplification,  this  raises the crucial  question of  how the remaining 84–90% coun‐
teracts  MITF  degradation  mediated  by  hyperactivated  ERK.  One  mechanism  could  in‐
volve  β-catenin  (molecule  which  regulates  cell  growth  and  adhesion  between  cells).  β-
catenin  can  induce  MITF  expression  through  a  LEF-1/TCF  binding  site  in  the  MITF
promoter  [130].  Although  mutations  in  β-catenin  are  rare  in  melanoma  [131],  nuclear
and/or  cytoplasmic  localization  of  β-catenin  was  found in  28% of  metastatic  melanoma
[132].  Therefore,  regardless  the  mechanism of  activation,  MITF was  shown to  be  a  key
mediator  of  switching between the  slow-growing invasive  phenotype and the  prolifera‐
tive phenotype in melanoma cells.
Recent  studies  have  shown the  role  of  germline  mutations  associated  with  MITF  func‐
tion.  Evidence  for  germline  mutations  in  melanomas  comes  from studies  with  relatives
of  patients  with  melanoma  with  increased  risk  of  melanoma  development,  indicating
the  presence  of  mutations  in  genes  with  high  penetrance  [for  review  133].  A  study
conducted by Bertolotto et  al.  involving patients  with melanoma and renal  cell  carcino‐
ma  (RCC)  supports  the  hypothesis  of  genetic  predisposition  for  both  cancers  [51].
MITF  stimulates  the  transcription  of  HIF1A,  the  pathway  of  which  is  targeted  by  kid‐
ney cancer  susceptibility  genes,  indicating  that  MITF might  have  a  role  in  conferring a
genetic  predisposition to co-occurring melanoma and RCC. A germline missense substi‐
tution  in  MITF  (Mi-E318K)  was  identified  occurring  at  a  significantly  higher  frequency
in  genetically  enriched patients  affected  with  melanoma,  RCC or  both  cancers.  Overall,
patients  bearing  the  Mi-E318K  genotype  had  more  than  fivefold  increased  risk  of  de‐
veloping  melanoma,  RCC  or  both  cancers.  The  E318K  variant  was  significantly  associ‐
ated  with  melanoma  in  a  large  case–control  sample.  The  variant  allele  was
significantly  over-represented in cases  with a  family history of  melanoma,  multiple  pri‐
mary  melanomas,  or  both.  The  variant  allele  was  also  associated  with  increased  nevus
count  and  no  blue  eye  colour.  In  addition,  Mi-E318K  enhanced  MITF  protein  binding
to  the  HIF1A  promoter  and  increased  its  transcriptional  activity.  Gene  expression
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profiling  from  RCC  cell  line  identified  a  Mi-E318K  signature  related  to  cell  growth,
proliferation  and  inflammation.  Therefore,  the  mutant  MITF  present  all  features  of  a
gain-of-function variant  associated with tumorigenesis.
4.2.3. MITF as therapeutic strategy?
The understanding of the tumor stage, microenvironment, and mechanisms employed in
phenotype switching have significant implications for clinical strategies in melanoma man‐
agement. The description of BRAF and KIT mutations provided the first basis for a molecular
classification of cutaneous melanoma and brought up insights about therapeutic approaches.
Therapies based on BRAF moves on direction of regulatory approval and incorporation as
standard therapy for patients with metastatic disease, as well as targeting mutated KIT has
also been established for melanoma patients. NRAS mutations have been known to be present
in a subset of melanomas and represent a complicated subgroup for targeted therapies.
Matching patient subgroups defined by genetic aberrations in the phosphoinositide 3-kinase
(PI3K) and p16/cyclin dependent kinase 4 (CDK4) pathways with appropriate targeted
therapies has not yet been realized. So, an increasing understanding of lineage-specific
transcriptional regulators, as MITF, and how they could play a role in melanoma pathophysi‐
ology provided other clues to therapies. Modulating MITF in a direct way with pharmacologic
inhibitors would be challenging, particularly if the interaction of MITF with certain promoter
regions on specific genes is desired. Reduction of MITF activity sensitizes melanoma cells to
different chemotherapeutic agents [for review 121]. Targeting MITF combined with BRAF or
cyclin-dependent kinase inhibitors is an exciting therapeutic strategy for melanoma patients.
One therapeutic strategy is target one or more of the post-translational processes that deter‐
mine MITF activity, stability, or degradation. Another approach is targeting the melanocyte-
specific mechanisms controlling MITF expression. Nonspecific histone deacetylases seem to
function in such a manner [134]. Furthermore, MITF and its target genes have been used as
diagnostic markers for melanoma [135]. As cited above, MITF-M isoform is involved in the in
vivo growth control and contribute to the phenotype of human melanoma whereas MITF-M
may qualify as a marker capable of identifying subgroups of melanoma patients with different
tumor biology and prognosis [136]. Many MITF transcriptional targets are emerging, and it is
likely that their identification may bring therapeutic strategies based on lineage-specific
conditions. One candidate is cyclin dependent kinase 2 (CDK2). This molecule seems to
contribute to deregulate cell cycle control via its transcriptional control by MITF, which is
unique in the melanocyte lineage due to its genomic location adjacent to a MITF. Another
molecule that seems to be regulated by MITF is BCL2 and it may contribute to resistance to
apoptosis in melanomas [134].
4.2.4 DNA repair genes – Dual effect of DNA repair genes in melanoma progression
Exposure to UV radiation from sunlight induces DNA damage, which can lead to melanocyte
carcinogenesis when not efficiently corrected. UV radiation may induce direct alterations
through formation of pyrimidine dimmers, indirect alterations through formation of reactive
oxygen species that may oxidize DNA bases and also induce DNA breaks. In a scenario where
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such alterations may facilitate the carcinogenic process, DNA repair systems are critical to
suppress malignant transformation. There are different DNA repair systems inside the cells,
which may repair a variety of DNA lesions, since mismatch base pairing formation during
replication process, oxidized DNA bases, bulky addictions, intra and interstrand damages and
single and double strand breaks. The main DNA repair systems are: Base excision repair (BER),
Nucleotide Excision Repair (NER), Mismatch Repair (MMR), Homologous Repair (HR) and
Non-Homologous End-Joinning Repair (NHEJ) [137].
The critical role of DNA repair systems in cancer suppression is observed in a diversity of
cancer predisposition syndromes which the main cause is due to mutations in DNA repair
genes. Mutations in genes of nucleotide excision repair (NER), which preferentially corrects
UV damages, caused the so-called Xeroderma Pigmentosum syndrome. The affected individuals
have a one thousand fold greater chances of developing skin cancer under the age of 20 years
[138], including melanomas, compared to DNA repair proficient individuals.
As  discussed  above,  genetic  variants  that  may  alter  the  functionality  of  DNA  repair
genes,  mainly genes from NER repair  systems,  may also modulate the susceptibility for
melanoma. DNA repair systems were pointed as a functional network that could contrib‐
ute  to  melanocyte  carcinogenesis  process  by  complete  inactivating  (such  as  in  XP  pa‐
tients)  or  by  differential  functionality  due  to  genetic  variants  associated  with
environmental  factors  such  as  UV  exposure.  However,  this  intuitive  thought  regarding
the  role  of  DNA repair  systems  restrict  to  the  initials  steps  of  melanoma development
has changed in the last years. A study published in 2008 [139] has suggested a new role
of  DNA  repair  systems  in  melanoma  progression  and  metastasis.  Aiming  at  the  better
understanding of primary melanoma to metastasis progression, the authors used a collec‐
tion of  frozen primary melanomas to  study their  gene expression by microarray.  Those
patients  that  had  primary  melanomas  included  in  the  study  had  a  follow  up  for  four
years. After that, 26 of 60 patients showed metastasis while the other 34 patients did not.
Gene expression of primary melanomas that originated metastasis (called M+ by the au‐
thors) was compared with the gene expression of primary melanomas that did not origi‐
nate  metastasis  (M-).  The  results  indicated  a  high  and  robust  significant  expression  of
genes involved with DNA replication (p  = 4.02 x 10-14)  and DNA repair genes (p  = 1.4 x
10-16)  in  those  M+  primary  melanomas.  Besides  the  high  expression  of  such  class  of
genes,  a  strong correlation with  Breslow index was  also  observed.  To certain  genes,  its
high expression was positively correlated to tumor thickness. To genes with low expres‐
sion in M+ primary melanomas compared to M- melanomas, a negative correlation with
tumor thickness was observed.
The study indentified a total of 48 genes with higher expression in M+, which are related to
DNA repair genes and genes related to maintenance of genetic stability in replication process
[139]. Among those genes, genes from the BER repair systems (a repair system strongly related
to repair oxidized bases and single strand breaks) such as OGG1 and EXO1 were high
expressed. A possible biological interpretation is that the high expression of these genes could
facilitate tumor growth and invasiveness, since base oxidation is the most frequent spontane‐
ous and deleterious lesions observed in actively replicating cells. Overexpression of genes of
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MMR repair systems was also observed. Since the inactivation of the MMR system leads to
DNA damage hypersensitivity, it is likely that over-expression of the MMR system could
improve the cellular resistance to DNA lesions. However, the main results indicate an over-
expression of genes related to rescue of stalled DNA replication forks, DNA double strand
breaks and interstrand crosslink repair. These processes, acting on the S-phase checkpoint and
post-replicative repair mechanisms, are essential for cell proliferation and survival by correct‐
ing eventual damages and replicative stress, such as cancer cells may exhibit higher rate of
DNA synthesis. Thus, by maintaining an elevate activity of such DNA repair systems and
checkpoints in S-phase during replicative stress, metastatic cancer cells can grow and survive,
and further be resistant to chemotherapy.
As example, a gene overexpressed in M+ melanomas was TOP2A, an enzyme that plays a role
in replication and chromosome segregation by solving torsional stress [140]. Moreover, cells
over-expressing TOP2A were more resistant to chemotherapeutic drugs such as alkylating
agents [141]. Finally, over-expression of genes related to FANC-BRCA pathways (genes acting
in double strand breaks repair and rescue of blocked replication forks) in melanomas M+
suggest the critical role that these process exerts on keeping the genetic stability in cancer cells
with metastatic fitness. These findings demonstrate an important duality of DNA repair genes
in tumor progression. First, the development of malignant cells from normal cells has been
credited to a reduction or lack of DNA repair genes, thereby allowing the accumulation of
mutations and subsequent transformation of the cells. This concept is well documented, since
the relationship of individuals with genetic predisposition to certain tumors, where such
predisposition may be is attributed to genes related to DNA repair or pathways that do support
to DNA repair pathways [142]. However, at some point in the progression of melanoma,
genetic stability appears to be a crucial factor to ensure that the tumor cells maintain the genetic
repertoire that guarantees the ability of invasion and metastasis. Thus, melanoma cells with
higher expression of DNA repair genes, would have greater capacity for metastasis due to
maintenance of genetic capability. The genetic stability suggested [139] is not limited to the
repair genes. Genes linked to telomere stability, as well as genes that ensure proper chromo‐
some separations were also highly expressed in melanomas M+. Another important implica‐
tion based on the results is that high expression of repair gene may be responsible for the
characteristic low response of metastatic melanoma to chemotherapy, since many of the
chemotherapeutic agents used to treat melanoma act causing DNA damage. It was also
observed a higher expression of genes correlated to resistance to chemotherapeutic agents such
as cisplatin and dacarbazine (e.g., BRCA1, XRCC5, XRCC6). In addition, other genes related
to the maintenance of DNA replication machinery were also highly expressed, leading to
translesion replication, thereby preventing the apoptosis signal being secondary to the arrest
of DNA/RNA polymerase.
Following studies, confirmed the high expression of FANC DNA repair genes in melanoma
samples when compared to normal skin and non-melanoma skin cancers [143]. Moreover,
there is a positive correlation regarding FANC genes and melanoma thickness by Breslow
index. Conversely, NER genes were significantly decreased in melanomas, albeit its expression
was not correlated with melanoma thickness. Immunohistochemistry of independent mela‐
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noma and non-melanoma skin cancers, confirmed the results previous discovered in gene
expression regarding FANC genes and melanomas. Interestingly, down regulation of NER
genes may have contributed to initial steps of melanomagenesis, however, the high expression
of gene products of DNA repair pathways, mainly those regarding to solve double strand
breaks, may be related to melanoma progression.
In another study, expression of DNA repair genes was associated with prognosis, disease
relapse, tumor thickness and response to chemotherapy in melanomas [144]. In that study,
high expression of genes RAD51, RAD52 and TOP2A was significantly associated to poor
relapse-free survival. Expression of RAD51 was 1.22 times greater in tumors from patients who
relapsed versus those who did not; the fold changes between tumors from relapsers and non-
relapsers for RAD52 and TOP2A were 1.16 and 1.12 respectively. RAD54B, RAD52, TOP2A and
RAD51 were also overexpressed in tumours from patients who died versus surviving patients.
As reported by the studies cited above [139;143], expression of DNA repair genes was also
correlated with tumor thickness and to mitotic rate. Finally, when the chemotherapy response
was analyzed, RAD51 and TOP2A had significantly higher expression in tumors from non-
responders compared to responders [144]. Finally, the results described point to new methods
for melanoma treatment, where in addition to chemotherapy and radiotherapy for melanoma
cells, the development of new drugs capable to modify the activity of proteins related to DNA
repair, may increase the efficiency of treatment.
4.2.5. PAX3 – Back to stemness?
The PAX family genes (from Paired Box) consist of transcriptional factors highly conserved
and also essential to development of different tissues during embryogenesis as well as essential
to maintenance of stem cells in the adult organism. Indeed, PAX genes are related to regulation
of several processes such as proliferation, migration, avoiding apoptosis and sustaining
stemness phenotype in undifferentiated cells. There are nine PAX proteins, of which PAX3 is
a particularly interesting protein for its function in regulating the development of melanocytes
and other cell types.
Together with SOX10, PAX3 regulate transcription of MITF [145] and c-RET [146] in melano‐
cytes. PAX3 is a key transcription factor during the development of the neural crest and its
derivatives in the embryo. The neural crest cells detach from the dorsal neural epithelium and
give origin to a diverse set of cells, including melanocytes. PAX3 starts its expression in neural
crest precursors that are further committed with melanocytic cells lineage, such as melano‐
blasts [147]. PAX3 exerts its activity by expressing MITF and repressing Dct (Dopachrome-
tautomerase), thus leading to an undifferentiated cell state [148]. When MITF levels reach a
threshold, a complex consisting of MITF and β-catenin binds to Dct promoter, abolishing PAX3
inhibition, which leads to Dct expression and melanocyte differentiation. It is thought that
upon terminal differentiation, the expression of PAX3 is reduced as suggested by initial studies
that reported no expression of PAX3 in normal skin melanocytes [148;149] PAX3 expression
has been described in nevi, in most primary melanoma tumors, melanoma cell lines [150-152].
The first study described the expression of PAX3 in 8/8 melanoma cell lines [150]. The study
also showed that PAX3 was commonly expressed in primary melanoma samples (21/58) but
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significantly less frequently in benign pigmented lesions (9/75). However, the following
studies found PAX3 expression in melanoblasts localized in hair follicles and also in mature
melanocytes in hair follicles, in 100% of the nevi examined, 94% of primary melanomas and
in 90% of metastatic melanomas examined [151;152].
A most complete study performed in melanocytic lesions [152], analyzed PAX3 expression in
normal skin, nevi, primary melanoma and melanoma metastases by immunohistochemistry.
PAX3 was expressed in all samples and in normal cells. PAX3 expression showed a pattern of
distribution characteristic of melanocytes (at epidermal-dermal boundary and along the hair
follicle). Moreover, PAX3-positive cells were fewer and had a weaker staining in normal skin,
as compared to nevi and melanomas. Co-expression of PAX3 with MITF was also observed in
all samples, however, in normal skin some cells expressed only MITF, highlighting the
differences in melanocyte phenotype. PAX3-positive cells were also co-stained with markers
of less or more melanocyte differentiation, such as HES1 and Melan-A respectively. The
samples indicated PAX3-positive cells co-stained with either markers, showing then a variable
differentiation status of epidermal and follicular melanocytes, however a higher proportion
of PAX3 and Melan-A positive cells. Finally, to further describe the phenotype of PAX3-
positive melanocytes and melanoma cells, antiapoptotic factor BCL2L1 and melanoma
progression marker MCAM were also analyzed in those cells. Regarding BCL2L1, a high
similar proportion of PAX3-positive cells were also BCL2L1 positive cells, in all samples, with
exception of melanoma metastases. These results suggest a role for PAX3 in regulation of
survival of melanocytes and melanomas. Regarding MCAM, all melanocytic lesions showed
its expression. Co-staining of MCAM and PAX3 increased in proportion from nevi to primary
melanoma to melanomas metastases. As suggested above, PAX3 also plays a role in regulating
genes involved in protecting cancer cells from apoptosis, as indicated by studies where the
down-regulation of PAX3 increased the levels of apoptosis [153;154]. One of the mechanisms
by which PAX3 may be involved with resistance to apoptosis resides in the fact that PAX3
interacts with the enhancer element of Bcl-XL gene, triggering its activation [155]. Another
mechanism described for the anti-apoptotic role of PAX3 is via the regulation of tumor
supressor PTEN [156]. In melanoma cells, the down regulation of PAX3 showed a dose-
dependent reduction of proliferation and induction of apoptosis when cells were treated with
cisplatin [157]. Indeed, PAX3 down-regulation lead to increase in p53 protein and also caspase3
(a critical protein involved with apoptosis).
Functional studies have clarified the PAX3 function on melanocytes/melanomas [158]. PAX3,
acting synergistically with SOX10, play a role in the regulation of MET expression. MET is a
transmembrane receptor tyrosine kinase activated by Hepatocyte Growth Factor (HGF) and
plays a role in normal development and in cell migration, growth, survival, differentiation,
angiogenesis [159]. The HGF-MET pathway is involved in melanocyte biology acting on
survival and maintenance of specific genes. MET is commonly over-expressed in melanoma
and is associated with a more aggressive phenotype in terms of invasion and metastasis
[160;161]. A strong correlation of expression of MET with PAX3 and SOX10 in primary
melanomas was observed [158]. Thus, the expression of PAX3 may facilitate melanoma
Melanoma Genetics: From Susceptibility to Progression
http://dx.doi.org/10.5772/54143
111
progression and metastasis through the expression of MET, a classical proto-oncogene
involved in invasion, metastasis, resistance of apoptosis, and tumor cell expansion.
PAX3 activities as a transcription factor were also analyzed by comparing melanocytic and
melanoma cell lines [162]. Initially, PAX3 binding to promoter regions of specific genes was
analyzed and a enrichment of binding in melanoma cells was observed in genes such as HES1,
SOX9 and NES (genes related to maintenance of stemness phenotype), CCNA2 and TPD52
(genes related to proliferation), BCL2L1, PTEN and TGFB1 (genes related to survival) and
MCAM, CSPG4 and CXCR4 (genes related to migration). Conversely, in melanocytic cell lines,
enrichment of PAX3 binding was just observed in HES1, SOX9, MCAM, TGFB1 and CSPG4,
however quantitative analysis indicated lower PAX3 binding activity in melanocyte promot‐
ers, as compared to melanomas. Finally, a correlation of PAX3 promoter binding levels in
melanocyte/melanoma cell line with gene expression of those genes indicated up-regulation
of SOX9, NES, CCNA2, TPD52, TGFB1, MCAM, CSPG4 and CXCR4 in melanoma. Regarding
BCL2L1 and PTEN, lower levels were observed in melanoma. In general, the study described
a correlation between PAX3 binding to the target gene and its expression level, identified
possible PAX3-regulated genes and also suggested the differential activity of PAX3 in
transcriptional activity in melanocytes and melanoma cells. The interpretation of the results
indicates critical features of the PAX3 function. Those genes up-regulated are genes related to
cancer progression (SOX9 and NES), genes involved with cell motility, spread and metastatic
potential (MCAM, CSPG4 and CXCR4) and with proliferation (TPD52). Moreover, down
regulation of PTEN also contributes to melanoma progression due to tumor suppression
activity of PTEN. Decreased of CDK2, BCL2 and MelanA (a melanocyte differentiation marker)
gene expression and inhibition of cell growth was observed with PAX3 knock-down in
melanoma cell lines, although the results were strongly cell line dependent [157]. Moreover,
an induced cell cycle arrest in S and G2/M phases and increase in apoptosis was also observed
in PAX3 knock-down melanoma cells, and in one cell line. Silencing of PAX3 induced terminal
differentiation.
In general, there is convincing evidence that PAX3 is expressed in melanomas and in mela‐
nocytic lesions, such as nevi. Indeed, PAX3 expression in melanomas may play a role in
progression regulating processes such as survival, proliferation, metastases and participating
in the maintenance of stemness. However, PAX3 seems expressed in a subset of differentiated
melanocytes. Further clarification of PAX3 function in these cells is necessary. Environmental
stimuli may be related to PAX3 expression in melanocytic lesions, as reported by up-regulation
of PAX3 under UV-induced loss of TFG-β signaling from keratinocytes [163]. Thus, PAX3 may
be a good target gene to understanding the melanomagenesis process and more studies
regarding its function are required.
4.2.6 TP53 gene and melanoma – What is its function?
The TP53 gene is thought to be the “guardian of the genome” due to its pleiotropic function
in protecting cells from genotoxic events, acting on cell cycle control, DNA repair and also
triggering apoptosis. In general, TP53 is frequently mutated in a diversity of cancer types and
its inactivation confers advantage to tumor initiation and progression. Regarding the sources
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of mutagenic agents to TP53, sun exposure is a potent mechanism of induction of TP53
mutations as suggested by the frequent occurrence of such mutations in skin cancers such as
basal cell carcinomas (BCC) and squamous cell carcinomas (SCC). In such skin cancers, UV-
related mutations (C to T and CC to TT transitions) are frequently described in TP53 and in
other genes, confirming then the role of UV exposure in skin cancers. As melanocytes from
exposed skin areas have UV-exposure as the major environmental factor to its tumorigenesis,
one could expect a high frequency of UV-related mutations in TP53 in melanomas, as those
found in the melanoma genome [19] and PTEN gene [90].
However, the proportion of primary melanomas harboring TP53 mutations is frequently low,
around 7% of melanoma samples, although ranging from 0 to 24% between individual studies
[38]. Data from meta-analysis of 645 melanoma specimens showed that only 13.2% were TP53
mutants, and more than half were UV signature changes [164]. Curiously, TP53 mutations
have been described in some nevi and in melanomas from XP patients [165]. In fact, on one
hand TP53 inactivating mutations play a role in cancer progression, however, on the other
hand, TP53 mutations in melanomas are frequently low. With this duality in mind, interesting
question arises: What is the function of TP53 in melanoma initiation and progression?
Moreover, is there a positive pressure to keep wild-type TP53 in melanomas? Recent functional
studies start to address these questions. Indeed, inactivation of p53 pathway may be relevant
for melanocyte transformation [166]. Study from melanocytes indicated that murine cells
engineered to have high levels of p53 developed less pigmented lesions, primary melanomas
and metastases [167]. Besides this feature, melanomas from elevated p53 levels had lower size
and growth rate, indicating a role for p53 as a suppressor of tumor development. Regarding
human melanocytes and melanoma cells, pharmacological activation of p53 by a specific
inhibitor of HDM-2, led cells to cell cycle arrest in low doses and to apoptosis in high doses.
In addition, chemical activation of p53 in primary human melanocytes and melanoma cells
demonstrated that these cells were far more sensitive to cell cycle arrest than to apoptosis.
Moreover, CDKN1A (also known as p21) was identified as the predominant network operating
in such tumor suppressor activity in melanocytes and melanomas [167]. In summary, such
study indicated an anti-proliferative role of p53, both in vivo and in vitro, as the preferential
mode for tumor suppression in melanocytes, indicating then the “need” for p53 supression to
allow melanomagenesis. However, as mutations are infrequent in TP53 from melanomas, a
possible way to inactivate p53 pathway is by regulating its activity. One possible mechanism
for the inactivation of the p53 pathway in melanoma may be attributed to mutations in the
CDKN2A locus. As discussed above, CDKN2A is frequently mutated, lost or even epigeneti‐
cally silenced in melanomas. Besides p16 protein, the locus also codes for p14ARF protein,
which is regulates HDM-2 protein, the classical negative regulator of p53. Thus, one manner
to contribute to melanoma progression through inactivation of p53-dependent pathways is by
inactivation of p14 protein, or even by amplification of HDM-2 gene. Under both circumstan‐
ces, abundance of p53 protein decreases. However, p14 mutations are frequently associated
with familial melanomas, which does not explain the somatic cases, HDM-2 amplification in
melanomas occurs in a very low frequency (ranging 3 to 5% - [168]) and high-level expression
of wild-type p53 can be found in melanoma tissues and cell lines [169].
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Some reports have indicated that high expression of p53 can be found in both melanoma
samples and melanoma cell lines. In addition, others reports have also indicated that this high
expression does not correlate with p53 functionality. Melanoma cell lines harboring wild-type
p53 showed transcriptional inactivity [169], a feature of melanoma cell lines that corroborates
with data showing different gene expression of p53 targets in melanomas compared with nevi,
strongly suggesting a dysfunctional p53 [166]. Moreover, melanoma cell lines with wild-type
p53 shows an absent p53 DNA-binding activity [170]. All these reports indicate that down‐
stream mechanisms could be operating to down-regulate p53 pathway in melanomas. One of
the challenges of melanoma genetics in the coming years is to identify and characterize those
downstream mechanisms, which certainly will improve our knowledge about p53 dysfunction
in melanoma biology as well as identifying possible windows for melanoma treatment. There
are at this moment critical candidates genes to act as negative regulator of p53 activity. Proteins
such as iASPP (Inhibitor of apoptosis-stimulating protein of p53) [171], delta Np73 [172], YB-1
[173] and Parc protein [174] has been described as p53 inhibitors. Alternatively, posttransla‐
tional modifications may also be responsible to p53 transcriptional silencing, such as phos‐
phorylation, acetylation, methylation, sumoylation and neddlyation. Some findings have
suggested that accumulation and increase in wild type p53 expression during melanoma
progression may be indicative of dysfunctional p53 activity, reflecting posttranslational p53
modifications. Cytoplasmatic functions of transcriptionally inactive p53 have also emerged as
a good hypothesis to a new p53 activity in either limit or promote tumor growth [175].
Additional reports have also confirmed the p53 transcriptional inability in melanomas [176].
The results from such study showed that p53 downstream genes involved in apoptosis have
low expression in melanoma metastases and melanoma cell lines. Conversely, genes involved
with cell cycle were over-expressed in melanoma cell lines. Curiously, little difference between
melanomas with wild-type p53 and mutant p53 could be observed regarding expression of
p53 target genes, which confirm the notion that possible negative regulators are involved in
the suppression of the p53 pathway. Even with down-regulation of p53 by using short-harpin
method, there was limited effect on p53 target genes in p53 wild-type melanomas, however to
melanocytes, p53 inhibition leads to alteration of several p53-dependent transcripts. An
interesting feature observed was related to the proliferative capacity in melanocytes and
melanomas, down regulation of p53 in melanocytes resulted in a gene expression similar to
melanomas and increased proliferation rates while in melanomas, down regulation of p53
contributed to decreased proliferation, corroborating the results described by an independent
study [177] (discussed below).
Although  melanomas  may  have  an  inability  to  exert  p53  full  transcriptional  capability,
the p53 accumulation observed in such melanomas may still  have basal  activity.  A cen‐
tral  question  is  to  understand  the  role  of  this  basal  p53  transcriptional  activity  in  pro‐
gression  of  melanomas.  Recent  functional  studies  start  to  address  this  interesting
question. Melanoma cells are described as largely adapted to certain stress such as endo‐
plasmic  reticulum  (ER)  stress  [178],  a  situation  where  melanomas  acquire  resistance  to
ER stress-induced apoptosis as well as resistance to chemotherapy [179]. This adaptative
response may be attributed to expression of  Mcl-1  protein,  which acts  antagonizing the
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pro-apoptotic  proteins  PUMA and NOXA. Under ER stress,  melanoma cells  accumulate
p53,  which  in  turn  (even  in  basal  activity)  induces  the  transcription  of  the  microRNA
miR149* [180]. The p53-dependent expression of miR149* decrease the activity of GSK3α,
resulting in Mcl-1 increase and consequent resistance to apoptosis. Moreover, decrease of
miR149* elevated the rate of cell death in these melanoma cells and inhibited melanoma
growth in a xenograft model. Finally, elevated expression of miR149 was found in mela‐
noma samples, associated with decrease of GSK3α and increase of Mcl-1.
Other elegant functional study indicated critical features of p53 role in melanocytes and
melanoma cells [177]. First, the study indicated that p53 may be dispensable for melanoma
cells due to lack of increase in DNA damage and enhanced proliferative potential in p53
depleted cells. Conversely, depletion of p53 in melanocytes increased mitotic defects. This last
result is consistent with animal models in which genetic depletion of p53 cooperates with cell
transformation [167]. Indeed, in melanoma cells p53 is kept in a basal state of functionality.
This basal activity showed to be critical to melanoma growth, as: (i) basal p53 activity leads to
HDM-2 expression, which in turn keeps the basal levels of p53; (ii) this basal level of p53 avoids
the activation of a p53-dependent pro-senescence program; (iii) in a basal state, p53 does not
induce expression of p21, which in turn does not inhibits E2F1. The following E2F1 activation
contributes to melanoma cell proliferation; (iv) expression of HMD-2 leads to activation of
E2F1 in a p53-independet manner, contributing to melanoma cell proliferation. Instead, the
“so-called” HDM-2 addiction in melanoma cells seems not to be related to melanocytes due
to maintenance of viability and absence of senescence when p53 is activated by MDM-2
depletion. In summary, this study [177] elucidates new functions of the p53-HDM-2 axis in
melanomas. Besides, the p53-HDM-2 axis in melanomas is now suggested as a promising
target for melanoma treatment, since the use of specific HDM-2 antagonist rescues the p53
activity, leading to melanoma growth suppression and melanoma cell death [181].
The identification of negative p53 regulators that keep p53 pathway dysfunctional seems
critical for a better understanding of the involvement of p53-dependent pathways in melano‐
magenesis and progression. Further functional studies will elucidate the intriguing questions
regarding the real function of p53 to melanoma biology: Why has TP53 low frequency of
mutations? How is p53 basal state maintained? What are p53 functions in melanomas?
4.2.7. MicroRNAs and melanoma – Another level of gene expression in melanomas
MicroRNAs (miRNAs) are small non-coding RNAs (21–23 nucleotides) encoded in the genome
of plants, invertebrates, and vertebrates. These small molecules bind imperfectly to the 3´
untranslated (3´UTR) regions of target messenger RNAs (mRNAs) thus, miRNAs are central
regulators of gene expression and can act both in a positive and a negative way to control
protein levels in the cell. More than a thousand miRNAs exist in the human genome and each
one can potentially regulate hundreds of mRNAs. Target prediction algorithms can be helpful
in identifying potential mRNA targets of the miRNA of interest and further they should be
validated by functional studies [182]. MicroRNAs play an important role in many cellular
processes, such as differentiation, proliferation, apoptosis, and stress response. Additionally,
they are key regulators in many diseases, including cancer [183]. These molecules regulate
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pathways in cancer by targeting various oncogenes and tumor suppressors and there is an
increasing body of evidence suggesting that genomic instability regions harbor miRNA genes
[184]. The first study to associate genomic instability regions, miRNAs and cancer was
published in 2002 [185]. The authors found frequent deletions at 13q14 involving miR-15 and
miR-16 genes in B-cell from chronic lymphocytic leukaemia. Since then, hundreds miRNAs
have been reported acting as oncogenes or tumour suppressor genes in a wide variety of
cancers [for review 183]. The first miRNAs described as involved in cancer formation was miR-
let-7 [186] and further the family of miRs let 7a and let 7b were reported to play a role in
melanomas [for review 187]. For example, miR-let 7-b acts as a negative regulator of melanoma
cell proliferation via regulation of cyclin D1, whereas miR-let-7a was demonstrated to regulate
the expression of integrin-β3 and the Ras [188]. So, modulation of miRNA expression is
increasingly thought to be an important mechanism by which tumour suppressor proteins and
oncoproteins exert some of their effects. Studies assessing the role of miRNAs in melanomas
are still very recent and many efforts have been made to identify the ‘melano-miRs’. Despite
the increasing number of studies (NCBI searching in September 2012 retrieved 162 results) a
small number of miRNAs were identified to regulate genes involved specifically in melano‐
magenesis and some of them will be discussed here.
The linking between expression of miR-137 and MITF expression, a crucial gene involved in
melanomas and already presented above have been described [189]. However, MITF seems to
be also regulated by miR-182, miR-148, and miR-340, respectively [190;191]. Additionally,
melanoma tumors preferentially express MITF mRNA isoforms with shorter 3´UTR, “to
avoid” miRNA post-transcriptional regulation. Although the translation of the transcripts can
be regulated by miRNAs the transcriptional regulation of miRNAs is still poorly known [192].
Some studies have searched for miRNA promoters that are specific to melanoma progression
[193]. In an opposite way, the authors identified miRNAs that are specifically regulated by
MITF transcription factor/oncoprotein and identified miR-146a, miR-221/222 and miR-363 as
MITF-regulated. This high-throughput identification of miRNA promoters and enhancer
regulatory elements sheds light on evolution of miRNA transcription and permits rapid
identification of transcriptional networks of miRNAs, inclusive in melanomas. Moreover,
expression of MITF has been recently shown to be involved in the regulation of DICER, the
central regulator of miRNA maturation and key enzyme involved in the formation of the RNA-
induced silencing complex. MITF binds and activates a conserved regulatory element up‐
stream of DICER’s transcriptional start site upon melanocyte differentiation [194]. Moreover,
when DICER was knocked out, melanocytes failed to survive [194].
Besides miRNAs “MITF regulators” or miRNAs “regulated by MITF”, other molecules with
known target genes in melanoma are also regulated by miRNAs. Recently an interesting
review focusing on miRNAs that act in major pathways of formation of melanomas: RAS-RAF-
MEK-ERK, p16INK4A-CDK4-RB, PIK3-AKT and the MITF pathway was published [195]. As
cited, mutation BRafV600E occurs in 50–70% of sporadic melanomas which active constitutively
the MEK/ERK signaling pathway, promoting tumor progression and metastasis through
enhanced cell proliferation, survival, motility and invasion. Two studies have investigated the
correlation between B-Raf mutational status and miRNA expression in melanomas and only
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one study linking three miRNAs to BRafV600E [196]. Recently, [197] a network of 420 miRNAs
deregulated in B-Raf/MKK/ERK pathway in melanoma cells whereas majority of which
modulate the expression of key cancer regulatory genes and functions was identified. In
addition to MEK/ERK pathway, new insights about miRNAs and p16INK4A-CDK4-RB pathway
have been described. The mains senescence pathway associated with miRNAs are p53/p21 and
p16/Rb pathways [for review 198]. Several miRNAs have been shown to be involved in the
regulation of pathways involved in cellular senescence exerting negative effects on cell cycle
progression, such as E2F family of transcription factors acting in cell cycle [198-200]. Recent
studies reported that E2F1 to E2F3 are targets of several miRNAs, such as miR-34a [201]. In
addition, miR-205 in human melanoma cells induces senescence by targeting E2F1 [202] and
miR-203 also induces senescence by targeting E2F3 in melanoma cells [203]. Therefore,
miRNA/E2F interaction is an important mechanism that leads melanomas cells to senescence.
Other studies have identified a cluster of miRNAs that are either involved in melanomagenesis
or predictors of survival. A study has identified the miR-506–514 cluster as a transforming
oncogene that regulates melanoma progression and melanocyte transformation [204]. More‐
over, the authors showed that ectopic expression of this cluster in melanocytes was sufficient
to transform them, activating cell growth, cell proliferation and migration/invasion along with
inhibiting apoptosis. Although this study did not identify any direct gene targets of the
miRNAs, further investigation is necessary because this cluster may reveal pathways that
contribute to both the initiation and the maintenance of melanoma. As presented above, studies
showed the increased expression of the miR-221/222 cluster associated with melanoma
progression [for review 205]. A cascade involving PLZF transcription factor as a repressor of
miR-221 and miR-222 by direct binding to their putative regulatory region was described [206].
These miRNAs regulate directly KIT and CDKN1B, respectively resulting in cell cycle inhibi‐
tion and differentiation. Thus, over-expression of these miRNAs cluster increases proliferation
and tumourigenesis and activates invasion/migration in melanomas.
Approaches investigating miRNAs expression are also based on gene silencing by CpG
methylation. Since miRNAs precursor genes are usually within regions of coding genes (intron
sequences, for example), dysfunction of these protein-coding genes by epigenetic mechanisms
may also be expected to cause aberrant regulation of the miRNA target genes [207]. For
example, miRNA-34a is highly methylated in melanoma cell lines and primary tumors and
additionally, it was described that MET transcript is miRNA-34a target [for review 188].
Besides miR-34a, the miR-34b, belonging to the same family, seems to have an important effect
on melanomas. A group of epigenetically regulated miRNA genes in melanoma cells, and
confirmed the upstream hypermethylated CpG island sequences of several miRNAs genes in
cell lines derived from different stages of melanoma, but not in melanocytes and keratinocytes
was identifies [208]. Among them, miR-34b expression reduced cell invasion and motility rates
of melanoma cell lines. After deep sequencing, the authors identified network modules that
are potentially regulated by miR-34b, and which suggest a mechanism for the role of miR-34b
in regulating normal cell motility and cytokinesis. Additionally, this same group identified the
epigenetic regulation of miR-375 in human melanomas. Melanoma cells were treated with one
demethylating agent (5-aza-2'-deoxycytidine) and it was identified the miR-375 highly
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methylated. Ectopic expression of miR-375 inhibited melanoma cell proliferation, invasion,
and cell motility, and induced cell shape changes, suggesting that miR-375 may have an
important function in the development and progression of human melanomas [209].
All of these studies investigated the biological functions of miRNAs and their contribution to
melanomagenesis. Other studies have attempted to identify miRNAs signatures for diagnostic
and prognostic, melanoma progression by comparing the expression profiles in different
stages of transformation, and others focused on specific pathways. Some of these studies will
be presented here. In 2007, assays were performed using the well established NCI-60 cancer
cell line panel and normal tissue [210]. The study was able to discriminate between the
malignancies, including melanomas cell lines whereas miR-146, miR-204 and miR-211
miRNAs shown to be highly expressed in melanomas. Large cohorts of miRNAs associated
with malignant transformation as well as with the progression and with metastatic coloniza‐
tion in melanocytes and subsets of melanoma cell lines also was identified [211]. Subsequently,
down regulation of miRNA-200c in melanocytes, melanoma cell lines, and patient samples
could be reported, whereas miRNA-205 and miRNA-23b were markedly reduced among
patient samples [212]. In contrast, miR-146a and miR-155 were upregulated in all analyzed
patients but none of the cell lines. Using deep sequencing approach of a diverse set of mela‐
noma and pigment cell libraries it was identified 539 known mature sequences along with the
prediction of 279 novel miRNAs candidates [213]. Some of these novel candidate miRNAs may
be specific to the melanocytic lineage and as such could be used as biomarkers in the early
detection of distant metastases by measuring the circulating levels in blood. The expression of
611 miRNAs in 59 metastatic specimens was profiled and the authors were able to identify a
“miRNA classifier” consisting of miR-150, miR-342-3p, miR-455-3p, miR-145, miR-155 and
miR-497 that were considered predictors of post-recurrence survival [214]. Similarly the
analyses of the miRNA expression profiling from melanoma lymph node metastases reported
a unique signature consisting of down regulation of miR-191, combined with up regulation of
miR-193a, miR-193b, miR-365, miR-338 and let-7. Together, this miRNAs also serves as
predictors of short-term survival in melanoma patients [215]. These findings indicate that
miRNAs are differentially expressed in melanoma subtypes and that their dysfunction can be
impacted by inherited gene variants, supporting the hypothesis that miRNA dysfunction
reflects biological differences in melanoma. Recently, the use of microarray analysis of
formalin-fixed and paraffin-embedded samples from different stages of melanomagenesis
identified differentially expressed microRNAs [216]. The miR-203 and miR-205 were differ‐
entially expressed between primary and metastatic melanomas and functional in vitro assays
validated this found. So, these results indicated that differentially expressed miRNAs that
could be useful as diagnostic or prognostic markers for melanoma.
As such, miRNAs represent a new class of molecules that might prove to be powerful cancer
biomarkers useful in future staging systems and used as stratification criteria in clinical trials
as well as treatment of patients with disseminated disease. It was demonstrated that miR-214
is over-expressed in metastatic melanoma cell lines as well as tumor specimens. MiR-214
regulates the expression of two transcription factors, AP-2c and AP-2a [217]. These molecules
have been previously shown to play major roles in melanoma metastasis via regulation of
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genes involved in invasion and angiogenesis. Histological examination of skin biopsies
remains the standard method for melanoma diagnosis and prognosis. Significant morpholog‐
ical overlap between benign and malignant lesions complicates diagnosis, and tumour
thickness is not always an accurate predictor of prognosis. For purpose of clinical management,
the microRNA profiling of clinical melanoma subtypes samples considering the somatic and
inherited mutations associated with melanomas, including the presence of one variant in a
miRNA binding site in the 3’UTR of the KRAS oncogene has been evaluated [218]. The authors
showed that miR-142-3p, miR-486, miR-214, miR-218, miR-362, miR-650 and miR-31 were
significantly correlated with acral as compared to non-acral melanomas. In addition, the
KRAS-variant was enriched in non-acral melanoma and that miR-137 under expression was
significantly associated with melanomas with the KRAS-variant. Recently, it was develop one
in situ measurement methodology to evaluate the miR-205 in a cohort of human melanomas
[219]. Based on previous findings, the authors hypothesized that decreased miR-205 would be
associated with more aggressive tumors. So, multiplexing miR-205 qISH (quantitative in situ
hybridization) with immunofluorescent assessment of S100/GP100 (melanocytic markers), the
authors evaluated quantitatively the miR-205 expression. Outcome was assessed on the Yale
Melanoma Discovery Cohort consisting of 105 primary melanoma specimens and then,
validated the results on an independent set of 206 primary melanomas. Measurement of
melanoma cell miR-205 levels shows a significantly shorter melanoma-specific survival in
patients with their low expression and it was significantly independent of stage, age, gender,
and Breslow depth. Low levels of miR-205 expression in melanoma cell quantified by ISH show
worse outcome, supporting the role of miR-205 as a tumor suppressor miRNA. This promising
result indicates that the quantification of miR-205 in situ suggests its potential use for future
prognostic or predictive models. Studies investigating the various roles of miRNAs in
melanocytes and melanoma are gaining momentum and should continue to provide fertile
ground for both clinical and basic research.
5. Conclusions
In this chapter we proposed to discuss the melanoma genetics, starting from the genes that
may confer susceptibility to the genes that may be involved with progression. Moreover, we
addressed the already known genes (here called as “old genetics”) as well as new genes that
have been discovered as involved in melanoma (here called as “new genetics). It is noteworthy
that the new technologies such as GWAS and deep-sequencing have improved our knowledge
about melanoma genetics. Nowadays we have critical information about the disease, such as
the clear involvement of UV in carcinogenic process and the many pathways that contribute
significantly to it. As could be observed, conversely to other cancer types where single genes
has great impact on susceptibility and progression, such as BRCA in breast and ovarian,
mismatch repair pathways and colorectal cancer or TP53 to Li-Fraumeni syndrome, a single
gene cannot be pointed as “the melanoma gene”. Huge amplitude of genetic pathways may
be related to melanoma progression and this same amplitude may be responsible for melano‐
ma metastasis and chemoresistance, making this neoplasia of complex management. However,
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in a biologist point of view such huge amplitude makes this neoplasia fascinating to under‐
stand, challenging researchers to approach the problem in creative ways.
It is tempting to assume that the more we know about melanoma biology, including melanoma
genetics, much more efficacious melanoma prevention and treatment will be. Heterogeneity
within the very same tumor will certainly hamper treatment. We will need to take it in account
in the days of personalized medicine. To this, improvement of technologies, coordinated
studies of gene-environment interactions, allied to functional studies and critical clinical trials,
will be necessary for the adequate translation of this body of information into patient benefit.
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